# PeptideScanner evidence objects: Daptomycin

Every published version of the records placed with Daptomycin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/daptomycin.json. Selected public evidence only; not medical advice.

- Objects: 102
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00093067-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00093067

> PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00093067-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00093067-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00093067-daptomycin-v1
- Content SHA-256: `c5ed60ff158dace447726ec8450dc50d8c6ae9d430a30b9df27d8bcc7209ac08`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00093067 ([`ctg-observation-nct00093067-2017-02-13-671f9afbf46f`](#source-ctg-observation-nct00093067-2017-02-13-671f9afbf46f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00093067-2017-02-13-671f9afbf46f`](#source-ctg-observation-nct00093067-2017-02-13-671f9afbf46f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00093067-2017-02-13-671f9afbf46f`](#source-ctg-observation-nct00093067-2017-02-13-671f9afbf46f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00093067-2017-02-13-671f9afbf46f`](#source-ctg-observation-nct00093067-2017-02-13-671f9afbf46f))

### Sources

<a id="source-ctg-observation-nct00093067-2017-02-13-671f9afbf46f"></a>
- **ClinicalTrials.gov record NCT00093067 · retained source version 2017-02-13:671f9afbf46f7d1a6de25f2e86e60fd0f5a9429bcd13efc6b408cffabb75ce5f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00093067) (`ctg-observation-nct00093067-2017-02-13-671f9afbf46f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00093067." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00093067-daptomycin-v1 SHA-256: c5ed60ff158dace447726ec8450dc50d8c6ae9d430a30b9df27d8bcc7209ac08.

---

<a id="clinicaltrials-gov-nct00295178-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00295178

> PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00295178-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-09-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00295178-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00295178-daptomycin-v1
- Content SHA-256: `d2c95cd20b7dd9168dcf0740b440510308da32d187be99963012684f4888e97e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00295178 ([`ctg-observation-nct00295178-2017-09-07-8b408c7c9090`](#source-ctg-observation-nct00295178-2017-09-07-8b408c7c9090))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00295178-2017-09-07-8b408c7c9090`](#source-ctg-observation-nct00295178-2017-09-07-8b408c7c9090))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00295178-2017-09-07-8b408c7c9090`](#source-ctg-observation-nct00295178-2017-09-07-8b408c7c9090))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00295178-2017-09-07-8b408c7c9090`](#source-ctg-observation-nct00295178-2017-09-07-8b408c7c9090))

### Sources

<a id="source-ctg-observation-nct00295178-2017-09-07-8b408c7c9090"></a>
- **ClinicalTrials.gov record NCT00295178 · retained source version 2017-09-07:8b408c7c90907e0daa3b5d72e6a6942212010de2bd40a16de3488b9a25856050** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00295178) (`ctg-observation-nct00295178-2017-09-07-8b408c7c9090`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00295178." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00295178-daptomycin-v1 SHA-256: d2c95cd20b7dd9168dcf0740b440510308da32d187be99963012684f4888e97e.

---

<a id="clinicaltrials-gov-nct00428844-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00428844

> PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00428844-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00428844-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00428844-daptomycin-v1
- Content SHA-256: `ff1eae87ab426743864c272e5b939122aefd24907c4286d86246fb8ef9a122fd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00428844 ([`ctg-observation-nct00428844-2018-01-31-697e8b6fce60`](#source-ctg-observation-nct00428844-2018-01-31-697e8b6fce60))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00428844-2018-01-31-697e8b6fce60`](#source-ctg-observation-nct00428844-2018-01-31-697e8b6fce60))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00428844-2018-01-31-697e8b6fce60`](#source-ctg-observation-nct00428844-2018-01-31-697e8b6fce60))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00428844-2018-01-31-697e8b6fce60`](#source-ctg-observation-nct00428844-2018-01-31-697e8b6fce60))

### Sources

<a id="source-ctg-observation-nct00428844-2018-01-31-697e8b6fce60"></a>
- **ClinicalTrials.gov record NCT00428844 · retained source version 2018-01-31:697e8b6fce605c7734918414d0e884261ded4d948d40d4a039e19be3d3f70e7d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00428844) (`ctg-observation-nct00428844-2018-01-31-697e8b6fce60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00428844." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00428844-daptomycin-v1 SHA-256: ff1eae87ab426743864c272e5b939122aefd24907c4286d86246fb8ef9a122fd.

---

<a id="clinicaltrials-gov-nct00467272-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00467272

> PeptideScanner retained ClinicalTrials.gov record NCT00467272 at 2026-11-15T22:01:45.056Z. Its registry update date was 2021-02-08, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00467272-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00467272-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00467272-daptomycin-v1
- Content SHA-256: `b197838b2a107f351ef3a62c78e0e161aa0d55d6294a37f965a9ca2e2f8e3651`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00467272 ([`ctg-observation-nct00467272-2021-02-08-02051a83e518`](#source-ctg-observation-nct00467272-2021-02-08-02051a83e518))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00467272 at 2026-11-15T22:01:45.056Z. Its registry update date was 2021-02-08, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00467272-2021-02-08-02051a83e518`](#source-ctg-observation-nct00467272-2021-02-08-02051a83e518))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00467272 at 2026-11-15T22:01:45.056Z. Its registry update date was 2021-02-08, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00467272-2021-02-08-02051a83e518`](#source-ctg-observation-nct00467272-2021-02-08-02051a83e518))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00467272-2021-02-08-02051a83e518`](#source-ctg-observation-nct00467272-2021-02-08-02051a83e518))

### Sources

<a id="source-ctg-observation-nct00467272-2021-02-08-02051a83e518"></a>
- **ClinicalTrials.gov record NCT00467272 · retained source version 2021-02-08:02051a83e5188ec7c68aeb25d506e4e5bb202f48c17db1c023166ec00a79e846** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00467272) (`ctg-observation-nct00467272-2021-02-08-02051a83e518`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00467272." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00467272-daptomycin-v1 SHA-256: b197838b2a107f351ef3a62c78e0e161aa0d55d6294a37f965a9ca2e2f8e3651.

---

<a id="clinicaltrials-gov-nct00538694-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00538694

> PeptideScanner retained ClinicalTrials.gov record NCT00538694 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00538694-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-11-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00538694-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00538694-daptomycin-v1
- Content SHA-256: `f0b4d1dc41ae3d14b9f891eefb6bc32240daa0be1c5e8005eaee36b49d7ecf5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00538694 ([`ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd`](#source-ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00538694 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd`](#source-ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00538694 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd`](#source-ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd`](#source-ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd))

### Sources

<a id="source-ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd"></a>
- **ClinicalTrials.gov record NCT00538694 · retained source version 2019-11-14:1e0f3232c2dd370d69d18ce3a2178964f8aff2c345ca7783ac051e7364aad84a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00538694) (`ctg-observation-nct00538694-2019-11-14-1e0f3232c2dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00538694." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00538694-daptomycin-v1 SHA-256: f0b4d1dc41ae3d14b9f891eefb6bc32240daa0be1c5e8005eaee36b49d7ecf5c.

---

<a id="clinicaltrials-gov-nct00540072-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00540072

> PeptideScanner retained ClinicalTrials.gov record NCT00540072 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00540072-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-11-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00540072-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00540072-daptomycin-v1
- Content SHA-256: `5cf706939b26db05b5e16a39a995ca9880db8209a43ca4a0e53a3ba0852a54b2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00540072 ([`ctg-observation-nct00540072-2019-11-14-a0ea795c9b97`](#source-ctg-observation-nct00540072-2019-11-14-a0ea795c9b97))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00540072 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00540072-2019-11-14-a0ea795c9b97`](#source-ctg-observation-nct00540072-2019-11-14-a0ea795c9b97))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00540072 at 2026-11-15T22:01:45.056Z. Its registry update date was 2019-11-14, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00540072-2019-11-14-a0ea795c9b97`](#source-ctg-observation-nct00540072-2019-11-14-a0ea795c9b97))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00540072-2019-11-14-a0ea795c9b97`](#source-ctg-observation-nct00540072-2019-11-14-a0ea795c9b97))

### Sources

<a id="source-ctg-observation-nct00540072-2019-11-14-a0ea795c9b97"></a>
- **ClinicalTrials.gov record NCT00540072 · retained source version 2019-11-14:a0ea795c9b974f349f095461c71616bbe4b69e82bfb90cf359ea0790a6c45b6d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00540072) (`ctg-observation-nct00540072-2019-11-14-a0ea795c9b97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00540072." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00540072-daptomycin-v1 SHA-256: 5cf706939b26db05b5e16a39a995ca9880db8209a43ca4a0e53a3ba0852a54b2.

---

<a id="clinicaltrials-gov-nct00663403-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00663403

> PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00663403-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-12-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00663403-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00663403-daptomycin-v1
- Content SHA-256: `0a643ea90128ee70c015df879276b16366e9a3eb05aaf5cad52a60b0a21e4a19`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00663403 ([`ctg-observation-nct00663403-2015-12-30-52677c904b06`](#source-ctg-observation-nct00663403-2015-12-30-52677c904b06))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00663403-2015-12-30-52677c904b06`](#source-ctg-observation-nct00663403-2015-12-30-52677c904b06))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00663403-2015-12-30-52677c904b06`](#source-ctg-observation-nct00663403-2015-12-30-52677c904b06))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00663403-2015-12-30-52677c904b06`](#source-ctg-observation-nct00663403-2015-12-30-52677c904b06))

### Sources

<a id="source-ctg-observation-nct00663403-2015-12-30-52677c904b06"></a>
- **ClinicalTrials.gov record NCT00663403 · retained source version 2015-12-30:52677c904b06b701b132422dddddaf7e6af60c7fa7140ee342d4a3f1aee308b7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00663403) (`ctg-observation-nct00663403-2015-12-30-52677c904b06`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00663403." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00663403-daptomycin-v1 SHA-256: 0a643ea90128ee70c015df879276b16366e9a3eb05aaf5cad52a60b0a21e4a19.

---

<a id="clinicaltrials-gov-nct00701636-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00701636

> PeptideScanner retained ClinicalTrials.gov record NCT00701636 at 2026-11-15T22:01:45.056Z. Its registry update date was 2016-08-29, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00701636-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00701636-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00701636-daptomycin-v1
- Content SHA-256: `f24f37908a63f30582b08fd1cb3d50355c2fd9480c06768d3e4f744e981440c8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00701636 ([`ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb`](#source-ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00701636 at 2026-11-15T22:01:45.056Z. Its registry update date was 2016-08-29, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb`](#source-ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00701636 at 2026-11-15T22:01:45.056Z. Its registry update date was 2016-08-29, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb`](#source-ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb`](#source-ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb))

### Sources

<a id="source-ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb"></a>
- **ClinicalTrials.gov record NCT00701636 · retained source version 2016-08-29:0c16f5fee3cb04b4440f65a9cea39f4f9aac2031fe115bbc0d661142d5a12bde** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00701636) (`ctg-observation-nct00701636-2016-08-29-0c16f5fee3cb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00701636." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00701636-daptomycin-v1 SHA-256: f24f37908a63f30582b08fd1cb3d50355c2fd9480c06768d3e4f744e981440c8.

---

<a id="clinicaltrials-gov-nct00711802-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00711802

> PeptideScanner retained ClinicalTrials.gov record NCT00711802 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00711802-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00711802-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00711802-daptomycin-v1
- Content SHA-256: `aef41bf2891660313d5fa1525b20546924020a9731eb35f8754e59667fa237ae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00711802 ([`ctg-observation-nct00711802-2018-09-05-4f604d580bcc`](#source-ctg-observation-nct00711802-2018-09-05-4f604d580bcc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00711802 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00711802-2018-09-05-4f604d580bcc`](#source-ctg-observation-nct00711802-2018-09-05-4f604d580bcc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00711802 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00711802-2018-09-05-4f604d580bcc`](#source-ctg-observation-nct00711802-2018-09-05-4f604d580bcc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00711802-2018-09-05-4f604d580bcc`](#source-ctg-observation-nct00711802-2018-09-05-4f604d580bcc))

### Sources

<a id="source-ctg-observation-nct00711802-2018-09-05-4f604d580bcc"></a>
- **ClinicalTrials.gov record NCT00711802 · retained source version 2018-09-05:4f604d580bcc7a56d890014e19b0055599df5559c79cc3626711da9bd2fbfd10** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00711802) (`ctg-observation-nct00711802-2018-09-05-4f604d580bcc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00711802." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00711802-daptomycin-v1 SHA-256: aef41bf2891660313d5fa1525b20546924020a9731eb35f8754e59667fa237ae.

---

<a id="clinicaltrials-gov-nct00772447-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00772447

> PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00772447-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00772447-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00772447-daptomycin-v1
- Content SHA-256: `bfe5b3e62916ea1f723b5d95ae4e0e11f6e1866fe009e7bc9b999b561906e94d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00772447 ([`ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a`](#source-ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a`](#source-ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a`](#source-ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a`](#source-ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a))

### Sources

<a id="source-ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a"></a>
- **ClinicalTrials.gov record NCT00772447 · retained source version 2015-03-09:4ea84e7bf49a5c0f3b0889d42baad109e81ff6d769a34838cb92d8bfc11c559b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00772447) (`ctg-observation-nct00772447-2015-03-09-4ea84e7bf49a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00772447." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00772447-daptomycin-v1 SHA-256: bfe5b3e62916ea1f723b5d95ae4e0e11f6e1866fe009e7bc9b999b561906e94d.

---

<a id="clinicaltrials-gov-nct00882557-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00882557

> PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00882557-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00882557-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00882557-daptomycin-v1
- Content SHA-256: `64d7be0e912884539443ab0ca7311986cc0a2662ddce4cbb0a5d466895c81ef6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00882557 ([`ctg-observation-nct00882557-2018-02-06-16bfdda73ca3`](#source-ctg-observation-nct00882557-2018-02-06-16bfdda73ca3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00882557-2018-02-06-16bfdda73ca3`](#source-ctg-observation-nct00882557-2018-02-06-16bfdda73ca3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00882557-2018-02-06-16bfdda73ca3`](#source-ctg-observation-nct00882557-2018-02-06-16bfdda73ca3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00882557-2018-02-06-16bfdda73ca3`](#source-ctg-observation-nct00882557-2018-02-06-16bfdda73ca3))

### Sources

<a id="source-ctg-observation-nct00882557-2018-02-06-16bfdda73ca3"></a>
- **ClinicalTrials.gov record NCT00882557 · retained source version 2018-02-06:16bfdda73ca3d128c5212001eb412ebda3556b24900229692d01080e6e433bdb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00882557) (`ctg-observation-nct00882557-2018-02-06-16bfdda73ca3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00882557." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00882557-daptomycin-v1 SHA-256: 64d7be0e912884539443ab0ca7311986cc0a2662ddce4cbb0a5d466895c81ef6.

---

<a id="clinicaltrials-gov-nct00942149-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT00942149

> PeptideScanner retained ClinicalTrials.gov record NCT00942149 at 2026-11-15T22:01:45.056Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct00942149-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00942149-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00942149-daptomycin-v1
- Content SHA-256: `a1f74bfebf503ce154c7fab1e184820461def6c17465024e3c1b985fa0c53f73`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00942149 ([`ctg-observation-nct00942149-2013-07-15-953c32e57a86`](#source-ctg-observation-nct00942149-2013-07-15-953c32e57a86))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00942149 at 2026-11-15T22:01:45.056Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00942149-2013-07-15-953c32e57a86`](#source-ctg-observation-nct00942149-2013-07-15-953c32e57a86))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00942149 at 2026-11-15T22:01:45.056Z. Its registry update date was 2013-07-15, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct00942149-2013-07-15-953c32e57a86`](#source-ctg-observation-nct00942149-2013-07-15-953c32e57a86))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00942149-2013-07-15-953c32e57a86`](#source-ctg-observation-nct00942149-2013-07-15-953c32e57a86))

### Sources

<a id="source-ctg-observation-nct00942149-2013-07-15-953c32e57a86"></a>
- **ClinicalTrials.gov record NCT00942149 · retained source version 2013-07-15:953c32e57a86edf13977e0d8bbb5e08f5b0c8217ca91068a8ebbe0e43216c286** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00942149) (`ctg-observation-nct00942149-2013-07-15-953c32e57a86`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00942149." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct00942149-daptomycin-v1 SHA-256: a1f74bfebf503ce154c7fab1e184820461def6c17465024e3c1b985fa0c53f73.

---

<a id="clinicaltrials-gov-nct01012089-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01012089

> PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01012089-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01012089-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01012089-daptomycin-v1
- Content SHA-256: `de92c1ef5b6f777a13364e0e285f73b76ae5a9ec2aff20c0c1a62539c6955bfa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01012089 ([`ctg-observation-nct01012089-2018-06-06-8e4f29658f83`](#source-ctg-observation-nct01012089-2018-06-06-8e4f29658f83))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01012089-2018-06-06-8e4f29658f83`](#source-ctg-observation-nct01012089-2018-06-06-8e4f29658f83))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01012089-2018-06-06-8e4f29658f83`](#source-ctg-observation-nct01012089-2018-06-06-8e4f29658f83))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01012089-2018-06-06-8e4f29658f83`](#source-ctg-observation-nct01012089-2018-06-06-8e4f29658f83))

### Sources

<a id="source-ctg-observation-nct01012089-2018-06-06-8e4f29658f83"></a>
- **ClinicalTrials.gov record NCT01012089 · retained source version 2018-06-06:8e4f29658f834721918ee76470621c5756cc7b75c227aea4109ec1f6f5ffe992** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01012089) (`ctg-observation-nct01012089-2018-06-06-8e4f29658f83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01012089." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01012089-daptomycin-v1 SHA-256: de92c1ef5b6f777a13364e0e285f73b76ae5a9ec2aff20c0c1a62539c6955bfa.

---

<a id="clinicaltrials-gov-nct01080963-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01080963

> PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01080963-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-04-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01080963-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01080963-daptomycin-v1
- Content SHA-256: `a6c261070fa9c38dfff06b57a7975bac86e2ad16f4e60079033d3650c5152f92`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01080963 ([`ctg-observation-nct01080963-2012-04-17-671ba6e828ed`](#source-ctg-observation-nct01080963-2012-04-17-671ba6e828ed))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01080963-2012-04-17-671ba6e828ed`](#source-ctg-observation-nct01080963-2012-04-17-671ba6e828ed))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01080963 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-04-17, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01080963-2012-04-17-671ba6e828ed`](#source-ctg-observation-nct01080963-2012-04-17-671ba6e828ed))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01080963-2012-04-17-671ba6e828ed`](#source-ctg-observation-nct01080963-2012-04-17-671ba6e828ed))

### Sources

<a id="source-ctg-observation-nct01080963-2012-04-17-671ba6e828ed"></a>
- **ClinicalTrials.gov record NCT01080963 · retained source version 2012-04-17:671ba6e828ede11968c8309358dde43a9f4aad860037a12384cc9c462c0a9822** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01080963) (`ctg-observation-nct01080963-2012-04-17-671ba6e828ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01080963." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01080963-daptomycin-v1 SHA-256: a6c261070fa9c38dfff06b57a7975bac86e2ad16f4e60079033d3650c5152f92.

---

<a id="clinicaltrials-gov-nct01184872-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01184872

> PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01184872-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-07-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01184872-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01184872-daptomycin-v1
- Content SHA-256: `56e8bf7bae1be110fe5924402711c402f69660ee64e295f0bc18ed8d8633d28c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01184872 ([`ctg-observation-nct01184872-2012-07-13-15b42c500c51`](#source-ctg-observation-nct01184872-2012-07-13-15b42c500c51))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01184872-2012-07-13-15b42c500c51`](#source-ctg-observation-nct01184872-2012-07-13-15b42c500c51))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01184872 at 2026-11-15T22:01:45.056Z. Its registry update date was 2012-07-13, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01184872-2012-07-13-15b42c500c51`](#source-ctg-observation-nct01184872-2012-07-13-15b42c500c51))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01184872-2012-07-13-15b42c500c51`](#source-ctg-observation-nct01184872-2012-07-13-15b42c500c51))

### Sources

<a id="source-ctg-observation-nct01184872-2012-07-13-15b42c500c51"></a>
- **ClinicalTrials.gov record NCT01184872 · retained source version 2012-07-13:15b42c500c51654b0c266b02a52b7fbeba87973ce667ee637f4063e3e1514eb6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01184872) (`ctg-observation-nct01184872-2012-07-13-15b42c500c51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01184872." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01184872-daptomycin-v1 SHA-256: 56e8bf7bae1be110fe5924402711c402f69660ee64e295f0bc18ed8d8633d28c.

---

<a id="clinicaltrials-gov-nct01191840-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01191840

> PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01191840-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01191840-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01191840-daptomycin-v1
- Content SHA-256: `ba3a2095329307da77b799ec9a84729d5d3d5d3c2a9fd6db0653dc5db930f97e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01191840 ([`ctg-observation-nct01191840-2018-01-05-05d52a916d2e`](#source-ctg-observation-nct01191840-2018-01-05-05d52a916d2e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01191840-2018-01-05-05d52a916d2e`](#source-ctg-observation-nct01191840-2018-01-05-05d52a916d2e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01191840-2018-01-05-05d52a916d2e`](#source-ctg-observation-nct01191840-2018-01-05-05d52a916d2e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01191840-2018-01-05-05d52a916d2e`](#source-ctg-observation-nct01191840-2018-01-05-05d52a916d2e))

### Sources

<a id="source-ctg-observation-nct01191840-2018-01-05-05d52a916d2e"></a>
- **ClinicalTrials.gov record NCT01191840 · retained source version 2018-01-05:05d52a916d2ef8f5dad2f991266146848edb6c44897e33f4de8eb4a3f195b040** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01191840) (`ctg-observation-nct01191840-2018-01-05-05d52a916d2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01191840." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01191840-daptomycin-v1 SHA-256: ba3a2095329307da77b799ec9a84729d5d3d5d3c2a9fd6db0653dc5db930f97e.

---

<a id="clinicaltrials-gov-nct01419184-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01419184

> PeptideScanner retained ClinicalTrials.gov record NCT01419184 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01419184-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01419184-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01419184-daptomycin-v1
- Content SHA-256: `d58aa51391f3e7c897e2fc036c91d27e60690e8b536ab30d7428e1a765403469`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01419184 ([`ctg-observation-nct01419184-2018-09-05-44ad56e9bb78`](#source-ctg-observation-nct01419184-2018-09-05-44ad56e9bb78))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01419184 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01419184-2018-09-05-44ad56e9bb78`](#source-ctg-observation-nct01419184-2018-09-05-44ad56e9bb78))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01419184 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-09-05, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01419184-2018-09-05-44ad56e9bb78`](#source-ctg-observation-nct01419184-2018-09-05-44ad56e9bb78))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01419184-2018-09-05-44ad56e9bb78`](#source-ctg-observation-nct01419184-2018-09-05-44ad56e9bb78))

### Sources

<a id="source-ctg-observation-nct01419184-2018-09-05-44ad56e9bb78"></a>
- **ClinicalTrials.gov record NCT01419184 · retained source version 2018-09-05:44ad56e9bb78677cb77a0f1eaa905f38270a53cccd69df4be326773323a6c6e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01419184) (`ctg-observation-nct01419184-2018-09-05-44ad56e9bb78`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01419184." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01419184-daptomycin-v1 SHA-256: d58aa51391f3e7c897e2fc036c91d27e60690e8b536ab30d7428e1a765403469.

---

<a id="clinicaltrials-gov-nct01549613-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01549613

> PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01549613-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-08-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01549613-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01549613-daptomycin-v1
- Content SHA-256: `a2cf9b1efefdcf9425ed33d69a21b7a68af42b6081e0dc4621f44c10197f7ac3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01549613 ([`ctg-observation-nct01549613-2014-08-01-233d82109157`](#source-ctg-observation-nct01549613-2014-08-01-233d82109157))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01549613-2014-08-01-233d82109157`](#source-ctg-observation-nct01549613-2014-08-01-233d82109157))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01549613-2014-08-01-233d82109157`](#source-ctg-observation-nct01549613-2014-08-01-233d82109157))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01549613-2014-08-01-233d82109157`](#source-ctg-observation-nct01549613-2014-08-01-233d82109157))

### Sources

<a id="source-ctg-observation-nct01549613-2014-08-01-233d82109157"></a>
- **ClinicalTrials.gov record NCT01549613 · retained source version 2014-08-01:233d821091577de361e4f035e766be033bb61dd7f28ff8c1b2dfd81988e8ef3c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01549613) (`ctg-observation-nct01549613-2014-08-01-233d82109157`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01549613." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01549613-daptomycin-v1 SHA-256: a2cf9b1efefdcf9425ed33d69a21b7a68af42b6081e0dc4621f44c10197f7ac3.

---

<a id="clinicaltrials-gov-nct01626560-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01626560

> PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01626560-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01626560-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01626560-daptomycin-v1
- Content SHA-256: `ea0ea8a2f5c938ed0805b5e6fec5c65edfff742c66fee569be936b56ce5e40e5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01626560 ([`ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648`](#source-ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648`](#source-ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648`](#source-ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648`](#source-ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648))

### Sources

<a id="source-ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648"></a>
- **ClinicalTrials.gov record NCT01626560 · retained source version 2015-03-20:bcd1d1ec5648e9bd6fcdf60055427878b84eb92594cffa33c826fef0dd71fa7a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01626560) (`ctg-observation-nct01626560-2015-03-20-bcd1d1ec5648`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01626560." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01626560-daptomycin-v1 SHA-256: ea0ea8a2f5c938ed0805b5e6fec5c65edfff742c66fee569be936b56ce5e40e5.

---

<a id="clinicaltrials-gov-nct01728376-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01728376

> PeptideScanner retained ClinicalTrials.gov record NCT01728376 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01728376-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01728376-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01728376-daptomycin-v1
- Content SHA-256: `f699cdd737e3795d033606bea30a3ecd0ae3c37a511c8682943a5b5c4f394e9d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01728376 ([`ctg-observation-nct01728376-2018-08-28-1268304b37ef`](#source-ctg-observation-nct01728376-2018-08-28-1268304b37ef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01728376 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01728376-2018-08-28-1268304b37ef`](#source-ctg-observation-nct01728376-2018-08-28-1268304b37ef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01728376 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01728376-2018-08-28-1268304b37ef`](#source-ctg-observation-nct01728376-2018-08-28-1268304b37ef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01728376-2018-08-28-1268304b37ef`](#source-ctg-observation-nct01728376-2018-08-28-1268304b37ef))

### Sources

<a id="source-ctg-observation-nct01728376-2018-08-28-1268304b37ef"></a>
- **ClinicalTrials.gov record NCT01728376 · retained source version 2018-08-28:1268304b37ef328399a0453863e364fc38e5805d10e92275915e0ba5484bc31a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01728376) (`ctg-observation-nct01728376-2018-08-28-1268304b37ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01728376." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01728376-daptomycin-v1 SHA-256: f699cdd737e3795d033606bea30a3ecd0ae3c37a511c8682943a5b5c4f394e9d.

---

<a id="clinicaltrials-gov-nct01792804-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01792804

> PeptideScanner retained ClinicalTrials.gov record NCT01792804 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-05-27, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01792804-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01792804-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01792804-daptomycin-v1
- Content SHA-256: `677f4ef829be952b6db508614ce6e2897a6e1590ad9abc475e97aa2ef0323df2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01792804 ([`ctg-observation-nct01792804-2020-05-27-08b0a51fffb9`](#source-ctg-observation-nct01792804-2020-05-27-08b0a51fffb9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01792804 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-05-27, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01792804-2020-05-27-08b0a51fffb9`](#source-ctg-observation-nct01792804-2020-05-27-08b0a51fffb9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01792804 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-05-27, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01792804-2020-05-27-08b0a51fffb9`](#source-ctg-observation-nct01792804-2020-05-27-08b0a51fffb9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01792804-2020-05-27-08b0a51fffb9`](#source-ctg-observation-nct01792804-2020-05-27-08b0a51fffb9))

### Sources

<a id="source-ctg-observation-nct01792804-2020-05-27-08b0a51fffb9"></a>
- **ClinicalTrials.gov record NCT01792804 · retained source version 2020-05-27:08b0a51fffb961380d5cd29bc76a95ebfd124dbb887ee5b452baea495d831028** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01792804) (`ctg-observation-nct01792804-2020-05-27-08b0a51fffb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01792804." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01792804-daptomycin-v1 SHA-256: 677f4ef829be952b6db508614ce6e2897a6e1590ad9abc475e97aa2ef0323df2.

---

<a id="clinicaltrials-gov-nct01922011-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT01922011

> PeptideScanner retained ClinicalTrials.gov record NCT01922011 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct01922011-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01922011-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01922011-daptomycin-v1
- Content SHA-256: `8228d7bbe19cc98a8346b2d7cbef334cf92a83036b265df6cc6a3a37b1272e62`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01922011 ([`ctg-observation-nct01922011-2018-08-28-f08f0b057611`](#source-ctg-observation-nct01922011-2018-08-28-f08f0b057611))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01922011 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01922011-2018-08-28-f08f0b057611`](#source-ctg-observation-nct01922011-2018-08-28-f08f0b057611))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01922011 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct01922011-2018-08-28-f08f0b057611`](#source-ctg-observation-nct01922011-2018-08-28-f08f0b057611))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01922011-2018-08-28-f08f0b057611`](#source-ctg-observation-nct01922011-2018-08-28-f08f0b057611))

### Sources

<a id="source-ctg-observation-nct01922011-2018-08-28-f08f0b057611"></a>
- **ClinicalTrials.gov record NCT01922011 · retained source version 2018-08-28:f08f0b0576115947c5848179f6b424870df5e19055572d67092b171712abeb28** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01922011) (`ctg-observation-nct01922011-2018-08-28-f08f0b057611`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01922011." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct01922011-daptomycin-v1 SHA-256: 8228d7bbe19cc98a8346b2d7cbef334cf92a83036b265df6cc6a3a37b1272e62.

---

<a id="clinicaltrials-gov-nct02660346-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT02660346

> PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct02660346-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02660346-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct02660346-daptomycin-v1
- Content SHA-256: `5912c94bfd04fb283906781ca269aaa2e215c40b15857199dbf4c4c68203561e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02660346 ([`ctg-observation-nct02660346-2018-02-01-b66252f26569`](#source-ctg-observation-nct02660346-2018-02-01-b66252f26569))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct02660346-2018-02-01-b66252f26569`](#source-ctg-observation-nct02660346-2018-02-01-b66252f26569))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct02660346-2018-02-01-b66252f26569`](#source-ctg-observation-nct02660346-2018-02-01-b66252f26569))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02660346-2018-02-01-b66252f26569`](#source-ctg-observation-nct02660346-2018-02-01-b66252f26569))

### Sources

<a id="source-ctg-observation-nct02660346-2018-02-01-b66252f26569"></a>
- **ClinicalTrials.gov record NCT02660346 · retained source version 2018-02-01:b66252f26569f58f24dd16076e6d3044aa27f212c1f1b686ac3d61bbba0ef598** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02660346) (`ctg-observation-nct02660346-2018-02-01-b66252f26569`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02660346." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct02660346-daptomycin-v1 SHA-256: 5912c94bfd04fb283906781ca269aaa2e215c40b15857199dbf4c4c68203561e.

---

<a id="clinicaltrials-gov-nct02972983-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT02972983

> PeptideScanner retained ClinicalTrials.gov record NCT02972983 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-09-22, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct02972983-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02972983-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct02972983-daptomycin-v1
- Content SHA-256: `7ab7ba268c85b2fdf4e814250bc7ab70f45b828fe07e2a5e8e196dd3ea42fe8b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02972983 ([`ctg-observation-nct02972983-2020-09-22-b3167737df29`](#source-ctg-observation-nct02972983-2020-09-22-b3167737df29))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02972983 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-09-22, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct02972983-2020-09-22-b3167737df29`](#source-ctg-observation-nct02972983-2020-09-22-b3167737df29))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02972983 at 2026-11-15T22:01:45.056Z. Its registry update date was 2020-09-22, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct02972983-2020-09-22-b3167737df29`](#source-ctg-observation-nct02972983-2020-09-22-b3167737df29))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02972983-2020-09-22-b3167737df29`](#source-ctg-observation-nct02972983-2020-09-22-b3167737df29))

### Sources

<a id="source-ctg-observation-nct02972983-2020-09-22-b3167737df29"></a>
- **ClinicalTrials.gov record NCT02972983 · retained source version 2020-09-22:b3167737df29b5cca641779902bf278b7d9aeef643e59eb5cb390ffb414d3ad1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02972983) (`ctg-observation-nct02972983-2020-09-22-b3167737df29`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02972983." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct02972983-daptomycin-v1 SHA-256: 7ab7ba268c85b2fdf4e814250bc7ab70f45b828fe07e2a5e8e196dd3ea42fe8b.

---

<a id="clinicaltrials-gov-nct03138733-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT03138733

> PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct03138733-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03138733-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct03138733-daptomycin-v1
- Content SHA-256: `532bf54db382e473cabf2673a8a2a2e8f6c34e560c6f4dac7140a8144feac77e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03138733 ([`ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d`](#source-ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d`](#source-ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d`](#source-ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d`](#source-ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d))

### Sources

<a id="source-ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d"></a>
- **ClinicalTrials.gov record NCT03138733 · retained source version 2026-10-07:ec5005bbfa8dd4a4ab4cd7ad4b8c41c04f1cc92ad3ef1c9bb25c0c2595662e46** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03138733) (`ctg-observation-nct03138733-2026-10-07-ec5005bbfa8d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03138733." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct03138733-daptomycin-v1 SHA-256: 532bf54db382e473cabf2673a8a2a2e8f6c34e560c6f4dac7140a8144feac77e.

---

<a id="clinicaltrials-gov-nct03426761-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT03426761

> PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct03426761-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-10-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03426761-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct03426761-daptomycin-v1
- Content SHA-256: `d5628d80a4de4621d0326de9a77976ab58679f5a9e35311df98d23edafd76a49`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03426761 ([`ctg-observation-nct03426761-2023-10-03-afe3db98cc9a`](#source-ctg-observation-nct03426761-2023-10-03-afe3db98cc9a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct03426761-2023-10-03-afe3db98cc9a`](#source-ctg-observation-nct03426761-2023-10-03-afe3db98cc9a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03426761 at 2026-11-15T22:01:45.056Z. Its registry update date was 2023-10-03, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct03426761-2023-10-03-afe3db98cc9a`](#source-ctg-observation-nct03426761-2023-10-03-afe3db98cc9a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03426761-2023-10-03-afe3db98cc9a`](#source-ctg-observation-nct03426761-2023-10-03-afe3db98cc9a))

### Sources

<a id="source-ctg-observation-nct03426761-2023-10-03-afe3db98cc9a"></a>
- **ClinicalTrials.gov record NCT03426761 · retained source version 2023-10-03:afe3db98cc9a29747cbdb6092e8b41c34f2676b9149ee33f135a7e8f81ddf53b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03426761) (`ctg-observation-nct03426761-2023-10-03-afe3db98cc9a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03426761." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct03426761-daptomycin-v1 SHA-256: d5628d80a4de4621d0326de9a77976ab58679f5a9e35311df98d23edafd76a49.

---

<a id="clinicaltrials-gov-nct04775953-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT04775953

> PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct04775953-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04775953-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct04775953-daptomycin-v1
- Content SHA-256: `385e019706846d7438336c804a6339f20ce9f7b716f55d8d632db6b88a509b80`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04775953 ([`ctg-observation-nct04775953-2024-12-10-81909edac1bb`](#source-ctg-observation-nct04775953-2024-12-10-81909edac1bb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct04775953-2024-12-10-81909edac1bb`](#source-ctg-observation-nct04775953-2024-12-10-81909edac1bb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct04775953-2024-12-10-81909edac1bb`](#source-ctg-observation-nct04775953-2024-12-10-81909edac1bb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04775953-2024-12-10-81909edac1bb`](#source-ctg-observation-nct04775953-2024-12-10-81909edac1bb))

### Sources

<a id="source-ctg-observation-nct04775953-2024-12-10-81909edac1bb"></a>
- **ClinicalTrials.gov record NCT04775953 · retained source version 2024-12-10:81909edac1bbbe7393820396fbd736ff7245402290cc94cd3c9fa813fe8791e6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04775953) (`ctg-observation-nct04775953-2024-12-10-81909edac1bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04775953." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct04775953-daptomycin-v1 SHA-256: 385e019706846d7438336c804a6339f20ce9f7b716f55d8d632db6b88a509b80.

---

<a id="clinicaltrials-gov-nct04983901-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT04983901

> PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct04983901-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04983901-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct04983901-daptomycin-v1
- Content SHA-256: `89cb5683ed353af834ab982c275d0a46e15418937593acacfe80084294c1e59f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04983901 ([`ctg-observation-nct04983901-2026-04-06-419889e63196`](#source-ctg-observation-nct04983901-2026-04-06-419889e63196))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct04983901-2026-04-06-419889e63196`](#source-ctg-observation-nct04983901-2026-04-06-419889e63196))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct04983901-2026-04-06-419889e63196`](#source-ctg-observation-nct04983901-2026-04-06-419889e63196))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04983901-2026-04-06-419889e63196`](#source-ctg-observation-nct04983901-2026-04-06-419889e63196))

### Sources

<a id="source-ctg-observation-nct04983901-2026-04-06-419889e63196"></a>
- **ClinicalTrials.gov record NCT04983901 · retained source version 2026-04-06:419889e63196148815f1507ab15f39c9fe8b51150afcf80e2da68c7e231858e8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04983901) (`ctg-observation-nct04983901-2026-04-06-419889e63196`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04983901." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct04983901-daptomycin-v1 SHA-256: 89cb5683ed353af834ab982c275d0a46e15418937593acacfe80084294c1e59f.

---

<a id="clinicaltrials-gov-nct05137119-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT05137119

> PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct05137119-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05137119-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct05137119-daptomycin-v1
- Content SHA-256: `fd2f1017643b54f7002f03f675f02253316284e9af91321f3b0c6e5cde211eda`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05137119 ([`ctg-observation-nct05137119-2026-05-06-7d715a382efc`](#source-ctg-observation-nct05137119-2026-05-06-7d715a382efc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct05137119-2026-05-06-7d715a382efc`](#source-ctg-observation-nct05137119-2026-05-06-7d715a382efc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct05137119-2026-05-06-7d715a382efc`](#source-ctg-observation-nct05137119-2026-05-06-7d715a382efc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05137119-2026-05-06-7d715a382efc`](#source-ctg-observation-nct05137119-2026-05-06-7d715a382efc))

### Sources

<a id="source-ctg-observation-nct05137119-2026-05-06-7d715a382efc"></a>
- **ClinicalTrials.gov record NCT05137119 · retained source version 2026-05-06:7d715a382efcd4af5a640f1085d03cdfc234fac66b6330d173f483e3651c3bf2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05137119) (`ctg-observation-nct05137119-2026-05-06-7d715a382efc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05137119." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct05137119-daptomycin-v1 SHA-256: fd2f1017643b54f7002f03f675f02253316284e9af91321f3b0c6e5cde211eda.

---

<a id="clinicaltrials-gov-nct07148960-daptomycin-v1"></a>

## ClinicalTrials.gov record NCT07148960

> PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin.

- Evidence object: `story:clinicaltrials-gov-nct07148960-daptomycin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07148960-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct07148960-daptomycin-v1
- Content SHA-256: `1b14bde12219d4520dca12a0bdc323f9b4770c5d66f812f95c639d8744997177`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07148960 ([`ctg-observation-nct07148960-2026-09-17-d12502c56102`](#source-ctg-observation-nct07148960-2026-09-17-d12502c56102))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct07148960-2026-09-17-d12502c56102`](#source-ctg-observation-nct07148960-2026-09-17-d12502c56102))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin. ([`ctg-observation-nct07148960-2026-09-17-d12502c56102`](#source-ctg-observation-nct07148960-2026-09-17-d12502c56102))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07148960-2026-09-17-d12502c56102`](#source-ctg-observation-nct07148960-2026-09-17-d12502c56102))

### Sources

<a id="source-ctg-observation-nct07148960-2026-09-17-d12502c56102"></a>
- **ClinicalTrials.gov record NCT07148960 · retained source version 2026-09-17:d12502c561020087946af1473544f3bb698ecdc8a96ab078415591e22f67395e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07148960) (`ctg-observation-nct07148960-2026-09-17-d12502c56102`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07148960." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#clinicaltrials-gov-nct07148960-daptomycin-v1 SHA-256: 1b14bde12219d4520dca12a0bdc323f9b4770c5d66f812f95c639d8744997177.

---

<a id="fda-drugs-anda091039-v1"></a>

## Drugs@FDA application ANDA091039

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091039 with status AP dated 2016-03-25, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091039:v1`
- Evidence domain: Regulatory
- Date in source: 2016-03-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091039/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda091039-v1
- Content SHA-256: `ddd9d787ff5e56ef6e769b8a662f0ea78d8a66ba8496a3757c38ce6446eb999c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091039 ([`fda-drugs-anda091039-2016-03-25-b71e16ac1954`](#source-fda-drugs-anda091039-2016-03-25-b71e16ac1954))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091039 with status AP dated 2016-03-25, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda091039-2016-03-25-b71e16ac1954`](#source-fda-drugs-anda091039-2016-03-25-b71e16ac1954))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091039 with status AP dated 2016-03-25, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda091039-2016-03-25-b71e16ac1954`](#source-fda-drugs-anda091039-2016-03-25-b71e16ac1954))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091039-2016-03-25-b71e16ac1954`](#source-fda-drugs-anda091039-2016-03-25-b71e16ac1954))

### Sources

<a id="source-fda-drugs-anda091039-2016-03-25-b71e16ac1954"></a>
- **Drugs@FDA application ANDA091039 · original submission status AP · 2016-03-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091039%22&limit=1) (`fda-drugs-anda091039-2016-03-25-b71e16ac1954`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091039." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda091039-v1 SHA-256: ddd9d787ff5e56ef6e769b8a662f0ea78d8a66ba8496a3757c38ce6446eb999c.

---

<a id="fda-drugs-anda202857-v1"></a>

## Drugs@FDA application ANDA202857

> The official Drugs@FDA dataset lists original submission 1 for ANDA 202857 with status AP dated 2014-09-12, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda202857:v1`
- Evidence domain: Regulatory
- Date in source: 2014-09-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda202857/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda202857-v1
- Content SHA-256: `36fbeeefa36a136fe1c96d63e4bcf306bca4287059ab1ede39b6219014f47672`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA202857 ([`fda-drugs-anda202857-2014-09-12-132d12eebe55`](#source-fda-drugs-anda202857-2014-09-12-132d12eebe55))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 202857 with status AP dated 2014-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda202857-2014-09-12-132d12eebe55`](#source-fda-drugs-anda202857-2014-09-12-132d12eebe55))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 202857 with status AP dated 2014-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda202857-2014-09-12-132d12eebe55`](#source-fda-drugs-anda202857-2014-09-12-132d12eebe55))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda202857-2014-09-12-132d12eebe55`](#source-fda-drugs-anda202857-2014-09-12-132d12eebe55))

### Sources

<a id="source-fda-drugs-anda202857-2014-09-12-132d12eebe55"></a>
- **Drugs@FDA application ANDA202857 · original submission status AP · 2014-09-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA202857%22&limit=1) (`fda-drugs-anda202857-2014-09-12-132d12eebe55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA202857." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda202857-v1 SHA-256: 36fbeeefa36a136fe1c96d63e4bcf306bca4287059ab1ede39b6219014f47672.

---

<a id="fda-drugs-anda205037-v1"></a>

## Drugs@FDA application ANDA205037

> The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda205037:v1`
- Evidence domain: Regulatory
- Date in source: 2018-06-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda205037/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda205037-v1
- Content SHA-256: `049402813475962b5844a24fd3040e705a353a338a8735bc231817d23d7d8889`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA205037 ([`fda-drugs-anda205037-2018-06-05-db0974d37f6a`](#source-fda-drugs-anda205037-2018-06-05-db0974d37f6a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda205037-2018-06-05-db0974d37f6a`](#source-fda-drugs-anda205037-2018-06-05-db0974d37f6a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda205037-2018-06-05-db0974d37f6a`](#source-fda-drugs-anda205037-2018-06-05-db0974d37f6a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda205037-2018-06-05-db0974d37f6a`](#source-fda-drugs-anda205037-2018-06-05-db0974d37f6a))

### Sources

<a id="source-fda-drugs-anda205037-2018-06-05-db0974d37f6a"></a>
- **Drugs@FDA application ANDA205037 · original submission status AP · 2018-06-05 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA205037%22&limit=1) (`fda-drugs-anda205037-2018-06-05-db0974d37f6a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA205037." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda205037-v1 SHA-256: 049402813475962b5844a24fd3040e705a353a338a8735bc231817d23d7d8889.

---

<a id="fda-drugs-anda206005-v1"></a>

## Drugs@FDA application ANDA206005

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206005 with status AP dated 2016-06-15, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206005:v1`
- Evidence domain: Regulatory
- Date in source: 2016-06-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206005/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda206005-v1
- Content SHA-256: `8a87377fa0c7e54a0c211b36821b70ad1fa3e29488b669c5b2b31aa01f5d75e3`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206005 ([`fda-drugs-anda206005-2016-06-15-340acd8747ca`](#source-fda-drugs-anda206005-2016-06-15-340acd8747ca))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206005 with status AP dated 2016-06-15, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda206005-2016-06-15-340acd8747ca`](#source-fda-drugs-anda206005-2016-06-15-340acd8747ca))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206005 with status AP dated 2016-06-15, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda206005-2016-06-15-340acd8747ca`](#source-fda-drugs-anda206005-2016-06-15-340acd8747ca))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206005-2016-06-15-340acd8747ca`](#source-fda-drugs-anda206005-2016-06-15-340acd8747ca))

### Sources

<a id="source-fda-drugs-anda206005-2016-06-15-340acd8747ca"></a>
- **Drugs@FDA application ANDA206005 · original submission status AP · 2016-06-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206005%22&limit=1) (`fda-drugs-anda206005-2016-06-15-340acd8747ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206005." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda206005-v1 SHA-256: 8a87377fa0c7e54a0c211b36821b70ad1fa3e29488b669c5b2b31aa01f5d75e3.

---

<a id="fda-drugs-anda206077-v1"></a>

## Drugs@FDA application ANDA206077

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206077:v1`
- Evidence domain: Regulatory
- Date in source: 2018-04-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206077/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda206077-v1
- Content SHA-256: `cb181bd1de6ab8322ed6b837ede4b19a295c175fb3629d9305e41dde09b5d17d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206077 ([`fda-drugs-anda206077-2018-04-11-a06b196537e6`](#source-fda-drugs-anda206077-2018-04-11-a06b196537e6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda206077-2018-04-11-a06b196537e6`](#source-fda-drugs-anda206077-2018-04-11-a06b196537e6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda206077-2018-04-11-a06b196537e6`](#source-fda-drugs-anda206077-2018-04-11-a06b196537e6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206077-2018-04-11-a06b196537e6`](#source-fda-drugs-anda206077-2018-04-11-a06b196537e6))

### Sources

<a id="source-fda-drugs-anda206077-2018-04-11-a06b196537e6"></a>
- **Drugs@FDA application ANDA206077 · original submission status AP · 2018-04-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206077%22&limit=1) (`fda-drugs-anda206077-2018-04-11-a06b196537e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206077." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda206077-v1 SHA-256: cb181bd1de6ab8322ed6b837ede4b19a295c175fb3629d9305e41dde09b5d17d.

---

<a id="fda-drugs-anda207104-v1"></a>

## Drugs@FDA application ANDA207104

> The official Drugs@FDA dataset lists original submission 1 for ANDA 207104 with status AP dated 2019-11-15, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda207104:v1`
- Evidence domain: Regulatory
- Date in source: 2019-11-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda207104/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda207104-v1
- Content SHA-256: `2115fe78b56709e7f577c2062102cbe9f40e76c06c06a43a4401f6adcb0cbcf2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA207104 ([`fda-drugs-anda207104-2019-11-15-b50b7be0f3b6`](#source-fda-drugs-anda207104-2019-11-15-b50b7be0f3b6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 207104 with status AP dated 2019-11-15, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda207104-2019-11-15-b50b7be0f3b6`](#source-fda-drugs-anda207104-2019-11-15-b50b7be0f3b6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 207104 with status AP dated 2019-11-15, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda207104-2019-11-15-b50b7be0f3b6`](#source-fda-drugs-anda207104-2019-11-15-b50b7be0f3b6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda207104-2019-11-15-b50b7be0f3b6`](#source-fda-drugs-anda207104-2019-11-15-b50b7be0f3b6))

### Sources

<a id="source-fda-drugs-anda207104-2019-11-15-b50b7be0f3b6"></a>
- **Drugs@FDA application ANDA207104 · original submission status AP · 2019-11-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA207104%22&limit=1) (`fda-drugs-anda207104-2019-11-15-b50b7be0f3b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA207104." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda207104-v1 SHA-256: 2115fe78b56709e7f577c2062102cbe9f40e76c06c06a43a4401f6adcb0cbcf2.

---

<a id="fda-drugs-anda208375-v1"></a>

## Drugs@FDA application ANDA208375

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208375 with status AP dated 2019-05-01, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208375:v1`
- Evidence domain: Regulatory
- Date in source: 2019-05-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208375/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda208375-v1
- Content SHA-256: `3b8def7cdf5beaf0c9aa262a1ac07dfcbcc22f6c251f8377129d4481143c8521`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208375 ([`fda-drugs-anda208375-2019-05-01-dcaf99e62285`](#source-fda-drugs-anda208375-2019-05-01-dcaf99e62285))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208375 with status AP dated 2019-05-01, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda208375-2019-05-01-dcaf99e62285`](#source-fda-drugs-anda208375-2019-05-01-dcaf99e62285))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208375 with status AP dated 2019-05-01, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda208375-2019-05-01-dcaf99e62285`](#source-fda-drugs-anda208375-2019-05-01-dcaf99e62285))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208375-2019-05-01-dcaf99e62285`](#source-fda-drugs-anda208375-2019-05-01-dcaf99e62285))

### Sources

<a id="source-fda-drugs-anda208375-2019-05-01-dcaf99e62285"></a>
- **Drugs@FDA application ANDA208375 · original submission status AP · 2019-05-01 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208375%22&limit=1) (`fda-drugs-anda208375-2019-05-01-dcaf99e62285`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208375." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda208375-v1 SHA-256: 3b8def7cdf5beaf0c9aa262a1ac07dfcbcc22f6c251f8377129d4481143c8521.

---

<a id="fda-drugs-anda211403-v1"></a>

## Drugs@FDA application ANDA211403

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211403 with status AP dated 2020-08-31, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211403:v1`
- Evidence domain: Regulatory
- Date in source: 2020-08-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211403/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda211403-v1
- Content SHA-256: `f240bf290acb83d1208d76056fcbf3f82b3ba91a6171386d61d4d4e178f7bcbd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211403 ([`fda-drugs-anda211403-2020-08-31-4415ecb517e5`](#source-fda-drugs-anda211403-2020-08-31-4415ecb517e5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211403 with status AP dated 2020-08-31, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda211403-2020-08-31-4415ecb517e5`](#source-fda-drugs-anda211403-2020-08-31-4415ecb517e5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211403 with status AP dated 2020-08-31, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda211403-2020-08-31-4415ecb517e5`](#source-fda-drugs-anda211403-2020-08-31-4415ecb517e5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211403-2020-08-31-4415ecb517e5`](#source-fda-drugs-anda211403-2020-08-31-4415ecb517e5))

### Sources

<a id="source-fda-drugs-anda211403-2020-08-31-4415ecb517e5"></a>
- **Drugs@FDA application ANDA211403 · original submission status AP · 2020-08-31 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211403%22&limit=1) (`fda-drugs-anda211403-2020-08-31-4415ecb517e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211403." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda211403-v1 SHA-256: f240bf290acb83d1208d76056fcbf3f82b3ba91a6171386d61d4d4e178f7bcbd.

---

<a id="fda-drugs-anda211961-v1"></a>

## Drugs@FDA application ANDA211961

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211961 with status AP dated 2019-06-24, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211961:v1`
- Evidence domain: Regulatory
- Date in source: 2019-06-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211961/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda211961-v1
- Content SHA-256: `94a656af35abc7e880d778c8a932e6e9a0e70e534363ad286dda9e831147944a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211961 ([`fda-drugs-anda211961-2019-06-24-f25ffc0a1772`](#source-fda-drugs-anda211961-2019-06-24-f25ffc0a1772))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211961 with status AP dated 2019-06-24, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda211961-2019-06-24-f25ffc0a1772`](#source-fda-drugs-anda211961-2019-06-24-f25ffc0a1772))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211961 with status AP dated 2019-06-24, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda211961-2019-06-24-f25ffc0a1772`](#source-fda-drugs-anda211961-2019-06-24-f25ffc0a1772))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211961-2019-06-24-f25ffc0a1772`](#source-fda-drugs-anda211961-2019-06-24-f25ffc0a1772))

### Sources

<a id="source-fda-drugs-anda211961-2019-06-24-f25ffc0a1772"></a>
- **Drugs@FDA application ANDA211961 · original submission status AP · 2019-06-24 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211961%22&limit=1) (`fda-drugs-anda211961-2019-06-24-f25ffc0a1772`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211961." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda211961-v1 SHA-256: 94a656af35abc7e880d778c8a932e6e9a0e70e534363ad286dda9e831147944a.

---

<a id="fda-drugs-anda212022-v1"></a>

## Drugs@FDA application ANDA212022

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212022 with status AP dated 2019-08-22, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212022:v1`
- Evidence domain: Regulatory
- Date in source: 2019-08-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212022/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212022-v1
- Content SHA-256: `46f838173a97a7e897ade06db4e2eab1a5bbbc6ed649f598bb0f4c4433c3a38d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212022 ([`fda-drugs-anda212022-2019-08-22-41a302f55213`](#source-fda-drugs-anda212022-2019-08-22-41a302f55213))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212022 with status AP dated 2019-08-22, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212022-2019-08-22-41a302f55213`](#source-fda-drugs-anda212022-2019-08-22-41a302f55213))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212022 with status AP dated 2019-08-22, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212022-2019-08-22-41a302f55213`](#source-fda-drugs-anda212022-2019-08-22-41a302f55213))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212022-2019-08-22-41a302f55213`](#source-fda-drugs-anda212022-2019-08-22-41a302f55213))

### Sources

<a id="source-fda-drugs-anda212022-2019-08-22-41a302f55213"></a>
- **Drugs@FDA application ANDA212022 · original submission status AP · 2019-08-22 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212022%22&limit=1) (`fda-drugs-anda212022-2019-08-22-41a302f55213`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212022." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212022-v1 SHA-256: 46f838173a97a7e897ade06db4e2eab1a5bbbc6ed649f598bb0f4c4433c3a38d.

---

<a id="fda-drugs-anda212250-v1"></a>

## Drugs@FDA application ANDA212250

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212250 with status AP dated 2021-04-21, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212250:v1`
- Evidence domain: Regulatory
- Date in source: 2021-04-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212250/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212250-v1
- Content SHA-256: `d2efb4cbdab5202bdf3b1dfd8b079de09cc2d80d84db1b9ef210780b3aeaa781`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212250 ([`fda-drugs-anda212250-2021-04-21-fec926cf3421`](#source-fda-drugs-anda212250-2021-04-21-fec926cf3421))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212250 with status AP dated 2021-04-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212250-2021-04-21-fec926cf3421`](#source-fda-drugs-anda212250-2021-04-21-fec926cf3421))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212250 with status AP dated 2021-04-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212250-2021-04-21-fec926cf3421`](#source-fda-drugs-anda212250-2021-04-21-fec926cf3421))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212250-2021-04-21-fec926cf3421`](#source-fda-drugs-anda212250-2021-04-21-fec926cf3421))

### Sources

<a id="source-fda-drugs-anda212250-2021-04-21-fec926cf3421"></a>
- **Drugs@FDA application ANDA212250 · original submission status AP · 2021-04-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212250%22&limit=1) (`fda-drugs-anda212250-2021-04-21-fec926cf3421`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212250." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212250-v1 SHA-256: d2efb4cbdab5202bdf3b1dfd8b079de09cc2d80d84db1b9ef210780b3aeaa781.

---

<a id="fda-drugs-anda212513-v1"></a>

## Drugs@FDA application ANDA212513

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212513 with status AP dated 2019-06-26, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212513:v1`
- Evidence domain: Regulatory
- Date in source: 2019-06-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212513/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212513-v1
- Content SHA-256: `56b50c7dfe47cefb3b98245981f5048247337345302c54ccabcffeb6e3316cbd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212513 ([`fda-drugs-anda212513-2019-06-26-30f608262097`](#source-fda-drugs-anda212513-2019-06-26-30f608262097))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212513 with status AP dated 2019-06-26, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212513-2019-06-26-30f608262097`](#source-fda-drugs-anda212513-2019-06-26-30f608262097))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212513 with status AP dated 2019-06-26, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212513-2019-06-26-30f608262097`](#source-fda-drugs-anda212513-2019-06-26-30f608262097))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212513-2019-06-26-30f608262097`](#source-fda-drugs-anda212513-2019-06-26-30f608262097))

### Sources

<a id="source-fda-drugs-anda212513-2019-06-26-30f608262097"></a>
- **Drugs@FDA application ANDA212513 · original submission status AP · 2019-06-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212513%22&limit=1) (`fda-drugs-anda212513-2019-06-26-30f608262097`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212513." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212513-v1 SHA-256: 56b50c7dfe47cefb3b98245981f5048247337345302c54ccabcffeb6e3316cbd.

---

<a id="fda-drugs-anda212667-v1"></a>

## Drugs@FDA application ANDA212667

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212667 with status AP dated 2019-07-12, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212667:v1`
- Evidence domain: Regulatory
- Date in source: 2019-07-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212667/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212667-v1
- Content SHA-256: `2575346876f1534ea436a1860320d67512d9bacefbe546cff3f1e0b743d6455b`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212667 ([`fda-drugs-anda212667-2019-07-12-941723898d81`](#source-fda-drugs-anda212667-2019-07-12-941723898d81))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212667 with status AP dated 2019-07-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212667-2019-07-12-941723898d81`](#source-fda-drugs-anda212667-2019-07-12-941723898d81))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212667 with status AP dated 2019-07-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda212667-2019-07-12-941723898d81`](#source-fda-drugs-anda212667-2019-07-12-941723898d81))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212667-2019-07-12-941723898d81`](#source-fda-drugs-anda212667-2019-07-12-941723898d81))

### Sources

<a id="source-fda-drugs-anda212667-2019-07-12-941723898d81"></a>
- **Drugs@FDA application ANDA212667 · original submission status AP · 2019-07-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212667%22&limit=1) (`fda-drugs-anda212667-2019-07-12-941723898d81`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212667." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda212667-v1 SHA-256: 2575346876f1534ea436a1860320d67512d9bacefbe546cff3f1e0b743d6455b.

---

<a id="fda-drugs-anda213171-v1"></a>

## Drugs@FDA application ANDA213171

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213171 with status AP dated 2021-09-02, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213171:v1`
- Evidence domain: Regulatory
- Date in source: 2021-09-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213171/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213171-v1
- Content SHA-256: `a9ebf7fb79b08f25a8e6eff42e95b4228fe6b8c70c402209da42872c68a3a936`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213171 ([`fda-drugs-anda213171-2021-09-02-488a493384e4`](#source-fda-drugs-anda213171-2021-09-02-488a493384e4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213171 with status AP dated 2021-09-02, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213171-2021-09-02-488a493384e4`](#source-fda-drugs-anda213171-2021-09-02-488a493384e4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213171 with status AP dated 2021-09-02, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213171-2021-09-02-488a493384e4`](#source-fda-drugs-anda213171-2021-09-02-488a493384e4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213171-2021-09-02-488a493384e4`](#source-fda-drugs-anda213171-2021-09-02-488a493384e4))

### Sources

<a id="source-fda-drugs-anda213171-2021-09-02-488a493384e4"></a>
- **Drugs@FDA application ANDA213171 · original submission status AP · 2021-09-02 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213171%22&limit=1) (`fda-drugs-anda213171-2021-09-02-488a493384e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213171." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213171-v1 SHA-256: a9ebf7fb79b08f25a8e6eff42e95b4228fe6b8c70c402209da42872c68a3a936.

---

<a id="fda-drugs-anda213396-v1"></a>

## Drugs@FDA application ANDA213396

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213396 with status AP dated 2024-08-01, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213396:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213396/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213396-v1
- Content SHA-256: `754a4c587f6558351380e4cff752936d46d7ce0401fa9d95073741b536105f98`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213396 ([`fda-drugs-anda213396-2024-08-01-f964c30e87f2`](#source-fda-drugs-anda213396-2024-08-01-f964c30e87f2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213396 with status AP dated 2024-08-01, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213396-2024-08-01-f964c30e87f2`](#source-fda-drugs-anda213396-2024-08-01-f964c30e87f2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213396 with status AP dated 2024-08-01, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213396-2024-08-01-f964c30e87f2`](#source-fda-drugs-anda213396-2024-08-01-f964c30e87f2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213396-2024-08-01-f964c30e87f2`](#source-fda-drugs-anda213396-2024-08-01-f964c30e87f2))

### Sources

<a id="source-fda-drugs-anda213396-2024-08-01-f964c30e87f2"></a>
- **Drugs@FDA application ANDA213396 · original submission status AP · 2024-08-01 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213396%22&limit=1) (`fda-drugs-anda213396-2024-08-01-f964c30e87f2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213396." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213396-v1 SHA-256: 754a4c587f6558351380e4cff752936d46d7ce0401fa9d95073741b536105f98.

---

<a id="fda-drugs-anda213425-v1"></a>

## Drugs@FDA application ANDA213425

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213425 with status AP dated 2020-08-20, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213425:v1`
- Evidence domain: Regulatory
- Date in source: 2020-08-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213425/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213425-v1
- Content SHA-256: `fbeee84463f778f1a6107cd2a83208c4d1e27bc846cbe73a0c8e24c54db74afa`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213425 ([`fda-drugs-anda213425-2020-08-20-d75408ab6598`](#source-fda-drugs-anda213425-2020-08-20-d75408ab6598))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213425 with status AP dated 2020-08-20, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213425-2020-08-20-d75408ab6598`](#source-fda-drugs-anda213425-2020-08-20-d75408ab6598))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213425 with status AP dated 2020-08-20, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213425-2020-08-20-d75408ab6598`](#source-fda-drugs-anda213425-2020-08-20-d75408ab6598))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213425-2020-08-20-d75408ab6598`](#source-fda-drugs-anda213425-2020-08-20-d75408ab6598))

### Sources

<a id="source-fda-drugs-anda213425-2020-08-20-d75408ab6598"></a>
- **Drugs@FDA application ANDA213425 · original submission status AP · 2020-08-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213425%22&limit=1) (`fda-drugs-anda213425-2020-08-20-d75408ab6598`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213425." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213425-v1 SHA-256: fbeee84463f778f1a6107cd2a83208c4d1e27bc846cbe73a0c8e24c54db74afa.

---

<a id="fda-drugs-anda213623-v1"></a>

## Drugs@FDA application ANDA213623

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213623 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213623:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213623/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213623-v1
- Content SHA-256: `c53a84c4ded6fa06e0589fbbc874c2c8a65422e3f6f659bbbbbb0a90b88d5b48`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213623 ([`fda-drugs-anda213623-2021-06-29-de43d26c376e`](#source-fda-drugs-anda213623-2021-06-29-de43d26c376e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213623 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213623-2021-06-29-de43d26c376e`](#source-fda-drugs-anda213623-2021-06-29-de43d26c376e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213623 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213623-2021-06-29-de43d26c376e`](#source-fda-drugs-anda213623-2021-06-29-de43d26c376e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213623-2021-06-29-de43d26c376e`](#source-fda-drugs-anda213623-2021-06-29-de43d26c376e))

### Sources

<a id="source-fda-drugs-anda213623-2021-06-29-de43d26c376e"></a>
- **Drugs@FDA application ANDA213623 · original submission status AP · 2021-06-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213623%22&limit=1) (`fda-drugs-anda213623-2021-06-29-de43d26c376e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213623." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213623-v1 SHA-256: c53a84c4ded6fa06e0589fbbc874c2c8a65422e3f6f659bbbbbb0a90b88d5b48.

---

<a id="fda-drugs-anda213786-v1"></a>

## Drugs@FDA application ANDA213786

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213786 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213786:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213786/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213786-v1
- Content SHA-256: `85e13f159ebf589b82db5a375e311756457f9cea864998682470b759f362c43d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213786 ([`fda-drugs-anda213786-2021-06-29-f2849c999826`](#source-fda-drugs-anda213786-2021-06-29-f2849c999826))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213786 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213786-2021-06-29-f2849c999826`](#source-fda-drugs-anda213786-2021-06-29-f2849c999826))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213786 with status AP dated 2021-06-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213786-2021-06-29-f2849c999826`](#source-fda-drugs-anda213786-2021-06-29-f2849c999826))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213786-2021-06-29-f2849c999826`](#source-fda-drugs-anda213786-2021-06-29-f2849c999826))

### Sources

<a id="source-fda-drugs-anda213786-2021-06-29-f2849c999826"></a>
- **Drugs@FDA application ANDA213786 · original submission status AP · 2021-06-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213786%22&limit=1) (`fda-drugs-anda213786-2021-06-29-f2849c999826`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213786." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213786-v1 SHA-256: 85e13f159ebf589b82db5a375e311756457f9cea864998682470b759f362c43d.

---

<a id="fda-drugs-anda213966-v1"></a>

## Drugs@FDA application ANDA213966

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213966:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213966/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213966-v1
- Content SHA-256: `04b4c5458e37451c7c0afd6e5088235b1dc9e190657375feccfcef19f4e8aac0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213966 ([`fda-drugs-anda213966-2023-08-07-673cdb9fcf8e`](#source-fda-drugs-anda213966-2023-08-07-673cdb9fcf8e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213966-2023-08-07-673cdb9fcf8e`](#source-fda-drugs-anda213966-2023-08-07-673cdb9fcf8e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda213966-2023-08-07-673cdb9fcf8e`](#source-fda-drugs-anda213966-2023-08-07-673cdb9fcf8e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213966-2023-08-07-673cdb9fcf8e`](#source-fda-drugs-anda213966-2023-08-07-673cdb9fcf8e))

### Sources

<a id="source-fda-drugs-anda213966-2023-08-07-673cdb9fcf8e"></a>
- **Drugs@FDA application ANDA213966 · original submission status AP · 2023-08-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213966%22&limit=1) (`fda-drugs-anda213966-2023-08-07-673cdb9fcf8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213966." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda213966-v1 SHA-256: 04b4c5458e37451c7c0afd6e5088235b1dc9e190657375feccfcef19f4e8aac0.

---

<a id="fda-drugs-anda215215-v1"></a>

## Drugs@FDA application ANDA215215

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215215 with status AP dated 2021-11-26, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215215:v1`
- Evidence domain: Regulatory
- Date in source: 2021-11-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215215/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215215-v1
- Content SHA-256: `159df1e609b541655dd5ff06d02bd1b1315bf334b700997922491efacc07088b`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215215 ([`fda-drugs-anda215215-2021-11-26-aec7e52fc026`](#source-fda-drugs-anda215215-2021-11-26-aec7e52fc026))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215215 with status AP dated 2021-11-26, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215215-2021-11-26-aec7e52fc026`](#source-fda-drugs-anda215215-2021-11-26-aec7e52fc026))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215215 with status AP dated 2021-11-26, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215215-2021-11-26-aec7e52fc026`](#source-fda-drugs-anda215215-2021-11-26-aec7e52fc026))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215215-2021-11-26-aec7e52fc026`](#source-fda-drugs-anda215215-2021-11-26-aec7e52fc026))

### Sources

<a id="source-fda-drugs-anda215215-2021-11-26-aec7e52fc026"></a>
- **Drugs@FDA application ANDA215215 · original submission status AP · 2021-11-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215215%22&limit=1) (`fda-drugs-anda215215-2021-11-26-aec7e52fc026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215215." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215215-v1 SHA-256: 159df1e609b541655dd5ff06d02bd1b1315bf334b700997922491efacc07088b.

---

<a id="fda-drugs-anda215316-v1"></a>

## Drugs@FDA application ANDA215316

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215316 with status AP dated 2021-08-24, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215316:v1`
- Evidence domain: Regulatory
- Date in source: 2021-08-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215316/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215316-v1
- Content SHA-256: `ec0015d53394d0d23f58accb7613cb1ff70d1d34af61b27542ccfe297d8cf3a4`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215316 ([`fda-drugs-anda215316-2021-08-24-f3abb1dba35c`](#source-fda-drugs-anda215316-2021-08-24-f3abb1dba35c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215316 with status AP dated 2021-08-24, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215316-2021-08-24-f3abb1dba35c`](#source-fda-drugs-anda215316-2021-08-24-f3abb1dba35c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215316 with status AP dated 2021-08-24, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215316-2021-08-24-f3abb1dba35c`](#source-fda-drugs-anda215316-2021-08-24-f3abb1dba35c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215316-2021-08-24-f3abb1dba35c`](#source-fda-drugs-anda215316-2021-08-24-f3abb1dba35c))

### Sources

<a id="source-fda-drugs-anda215316-2021-08-24-f3abb1dba35c"></a>
- **Drugs@FDA application ANDA215316 · original submission status AP · 2021-08-24 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215316%22&limit=1) (`fda-drugs-anda215316-2021-08-24-f3abb1dba35c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215316." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215316-v1 SHA-256: ec0015d53394d0d23f58accb7613cb1ff70d1d34af61b27542ccfe297d8cf3a4.

---

<a id="fda-drugs-anda215890-v1"></a>

## Drugs@FDA application ANDA215890

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215890 with status AP dated 2022-08-18, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215890:v1`
- Evidence domain: Regulatory
- Date in source: 2022-08-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215890/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215890-v1
- Content SHA-256: `469a71a93a9126e4fd66113f43603aaf1ac011f996d9e31801ee2c5d1c026af0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215890 ([`fda-drugs-anda215890-2022-08-18-7abb42f57f1f`](#source-fda-drugs-anda215890-2022-08-18-7abb42f57f1f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215890 with status AP dated 2022-08-18, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215890-2022-08-18-7abb42f57f1f`](#source-fda-drugs-anda215890-2022-08-18-7abb42f57f1f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215890 with status AP dated 2022-08-18, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda215890-2022-08-18-7abb42f57f1f`](#source-fda-drugs-anda215890-2022-08-18-7abb42f57f1f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215890-2022-08-18-7abb42f57f1f`](#source-fda-drugs-anda215890-2022-08-18-7abb42f57f1f))

### Sources

<a id="source-fda-drugs-anda215890-2022-08-18-7abb42f57f1f"></a>
- **Drugs@FDA application ANDA215890 · original submission status AP · 2022-08-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215890%22&limit=1) (`fda-drugs-anda215890-2022-08-18-7abb42f57f1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215890." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda215890-v1 SHA-256: 469a71a93a9126e4fd66113f43603aaf1ac011f996d9e31801ee2c5d1c026af0.

---

<a id="fda-drugs-anda216413-v1"></a>

## Drugs@FDA application ANDA216413

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216413 with status AP dated 2022-09-23, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216413:v1`
- Evidence domain: Regulatory
- Date in source: 2022-09-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216413/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda216413-v1
- Content SHA-256: `b5078496ebb68e266f47f45e33228df6435bf362bef836db9a144e26e620d191`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216413 ([`fda-drugs-anda216413-2022-09-23-8c2a998fcaa2`](#source-fda-drugs-anda216413-2022-09-23-8c2a998fcaa2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216413 with status AP dated 2022-09-23, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda216413-2022-09-23-8c2a998fcaa2`](#source-fda-drugs-anda216413-2022-09-23-8c2a998fcaa2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216413 with status AP dated 2022-09-23, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda216413-2022-09-23-8c2a998fcaa2`](#source-fda-drugs-anda216413-2022-09-23-8c2a998fcaa2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216413-2022-09-23-8c2a998fcaa2`](#source-fda-drugs-anda216413-2022-09-23-8c2a998fcaa2))

### Sources

<a id="source-fda-drugs-anda216413-2022-09-23-8c2a998fcaa2"></a>
- **Drugs@FDA application ANDA216413 · original submission status AP · 2022-09-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216413%22&limit=1) (`fda-drugs-anda216413-2022-09-23-8c2a998fcaa2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216413." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda216413-v1 SHA-256: b5078496ebb68e266f47f45e33228df6435bf362bef836db9a144e26e620d191.

---

<a id="fda-drugs-anda216445-v1"></a>

## Drugs@FDA application ANDA216445

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216445 with status AP dated 2022-12-23, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216445:v1`
- Evidence domain: Regulatory
- Date in source: 2022-12-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216445/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda216445-v1
- Content SHA-256: `f4d1a7b07b0e1c53eb393c336e93b1a50cd561d1a69fc5aac732eeb6b4c3c391`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216445 ([`fda-drugs-anda216445-2022-12-23-6417818f603e`](#source-fda-drugs-anda216445-2022-12-23-6417818f603e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216445 with status AP dated 2022-12-23, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda216445-2022-12-23-6417818f603e`](#source-fda-drugs-anda216445-2022-12-23-6417818f603e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216445 with status AP dated 2022-12-23, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda216445-2022-12-23-6417818f603e`](#source-fda-drugs-anda216445-2022-12-23-6417818f603e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216445-2022-12-23-6417818f603e`](#source-fda-drugs-anda216445-2022-12-23-6417818f603e))

### Sources

<a id="source-fda-drugs-anda216445-2022-12-23-6417818f603e"></a>
- **Drugs@FDA application ANDA216445 · original submission status AP · 2022-12-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216445%22&limit=1) (`fda-drugs-anda216445-2022-12-23-6417818f603e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216445." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda216445-v1 SHA-256: f4d1a7b07b0e1c53eb393c336e93b1a50cd561d1a69fc5aac732eeb6b4c3c391.

---

<a id="fda-drugs-anda217215-v1"></a>

## Drugs@FDA application ANDA217215

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217215 with status AP dated 2024-08-29, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217215:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217215/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda217215-v1
- Content SHA-256: `a0983d0f759a3773a22f712f220c919c299fe66152a88e9b9ab7a6bd495e5eea`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217215 ([`fda-drugs-anda217215-2024-08-29-3ee0bf90eb33`](#source-fda-drugs-anda217215-2024-08-29-3ee0bf90eb33))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217215 with status AP dated 2024-08-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda217215-2024-08-29-3ee0bf90eb33`](#source-fda-drugs-anda217215-2024-08-29-3ee0bf90eb33))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217215 with status AP dated 2024-08-29, and names daptomycin among the application record's active ingredients. ([`fda-drugs-anda217215-2024-08-29-3ee0bf90eb33`](#source-fda-drugs-anda217215-2024-08-29-3ee0bf90eb33))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217215-2024-08-29-3ee0bf90eb33`](#source-fda-drugs-anda217215-2024-08-29-3ee0bf90eb33))

### Sources

<a id="source-fda-drugs-anda217215-2024-08-29-3ee0bf90eb33"></a>
- **Drugs@FDA application ANDA217215 · original submission status AP · 2024-08-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217215%22&limit=1) (`fda-drugs-anda217215-2024-08-29-3ee0bf90eb33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217215." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-anda217215-v1 SHA-256: a0983d0f759a3773a22f712f220c919c299fe66152a88e9b9ab7a6bd495e5eea.

---

<a id="fda-drugs-nda021572-v1"></a>

## Drugs@FDA application NDA021572

> The official Drugs@FDA dataset lists original submission 1 for NDA 021572 with status AP dated 2003-09-12, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021572:v1`
- Evidence domain: Regulatory
- Date in source: 2003-09-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021572/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda021572-v1
- Content SHA-256: `f25214ca15773d1e36ef285ce888e3bce5ae556e6ec3b41f0a840e6b727ec568`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021572 ([`fda-drugs-nda021572-2003-09-12-a3831b8093fc`](#source-fda-drugs-nda021572-2003-09-12-a3831b8093fc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021572 with status AP dated 2003-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda021572-2003-09-12-a3831b8093fc`](#source-fda-drugs-nda021572-2003-09-12-a3831b8093fc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021572 with status AP dated 2003-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda021572-2003-09-12-a3831b8093fc`](#source-fda-drugs-nda021572-2003-09-12-a3831b8093fc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021572-2003-09-12-a3831b8093fc`](#source-fda-drugs-nda021572-2003-09-12-a3831b8093fc))

### Sources

<a id="source-fda-drugs-nda021572-2003-09-12-a3831b8093fc"></a>
- **Drugs@FDA application NDA021572 · original submission status AP · 2003-09-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021572%22&limit=1) (`fda-drugs-nda021572-2003-09-12-a3831b8093fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021572." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda021572-v1 SHA-256: f25214ca15773d1e36ef285ce888e3bce5ae556e6ec3b41f0a840e6b727ec568.

---

<a id="fda-drugs-nda208385-v1"></a>

## Drugs@FDA application NDA208385

> The official Drugs@FDA dataset lists original submission 1 for NDA 208385 with status AP dated 2017-09-12, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208385:v1`
- Evidence domain: Regulatory
- Date in source: 2017-09-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208385/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda208385-v1
- Content SHA-256: `1c0d6f643758b967c4555190989532629af680a104b67f7bb25d0067000c825e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208385 ([`fda-drugs-nda208385-2017-09-12-996295540486`](#source-fda-drugs-nda208385-2017-09-12-996295540486))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208385 with status AP dated 2017-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda208385-2017-09-12-996295540486`](#source-fda-drugs-nda208385-2017-09-12-996295540486))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208385 with status AP dated 2017-09-12, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda208385-2017-09-12-996295540486`](#source-fda-drugs-nda208385-2017-09-12-996295540486))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208385-2017-09-12-996295540486`](#source-fda-drugs-nda208385-2017-09-12-996295540486))

### Sources

<a id="source-fda-drugs-nda208385-2017-09-12-996295540486"></a>
- **Drugs@FDA application NDA208385 · original submission status AP · 2017-09-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208385%22&limit=1) (`fda-drugs-nda208385-2017-09-12-996295540486`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208385." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda208385-v1 SHA-256: 1c0d6f643758b967c4555190989532629af680a104b67f7bb25d0067000c825e.

---

<a id="fda-drugs-nda209949-v1"></a>

## Drugs@FDA application NDA209949

> The official Drugs@FDA dataset lists original submission 1 for NDA 209949 with status AP dated 2017-10-20, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda209949:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda209949/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda209949-v1
- Content SHA-256: `d44201e758d70e6db507058c82bf1fdf877c9924aca89f02fc37ebd0b394f183`

### Claims and source pins

#### Headline

Drugs@FDA application NDA209949 ([`fda-drugs-nda209949-2017-10-20-4e40e78744fd`](#source-fda-drugs-nda209949-2017-10-20-4e40e78744fd))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 209949 with status AP dated 2017-10-20, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda209949-2017-10-20-4e40e78744fd`](#source-fda-drugs-nda209949-2017-10-20-4e40e78744fd))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 209949 with status AP dated 2017-10-20, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda209949-2017-10-20-4e40e78744fd`](#source-fda-drugs-nda209949-2017-10-20-4e40e78744fd))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda209949-2017-10-20-4e40e78744fd`](#source-fda-drugs-nda209949-2017-10-20-4e40e78744fd))

### Sources

<a id="source-fda-drugs-nda209949-2017-10-20-4e40e78744fd"></a>
- **Drugs@FDA application NDA209949 · original submission status AP · 2017-10-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA209949%22&limit=1) (`fda-drugs-nda209949-2017-10-20-4e40e78744fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA209949." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda209949-v1 SHA-256: d44201e758d70e6db507058c82bf1fdf877c9924aca89f02fc37ebd0b394f183.

---

<a id="fda-drugs-nda210282-v1"></a>

## Drugs@FDA application NDA210282

> The official Drugs@FDA dataset lists original submission 1 for NDA 210282 with status AP dated 2021-06-21, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda210282:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda210282/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda210282-v1
- Content SHA-256: `d335f79fe269249a60750c0549a271830880db174b9db97004a8e2a6adbf0ff1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA210282 ([`fda-drugs-nda210282-2021-06-21-56491d9f60f5`](#source-fda-drugs-nda210282-2021-06-21-56491d9f60f5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 210282 with status AP dated 2021-06-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda210282-2021-06-21-56491d9f60f5`](#source-fda-drugs-nda210282-2021-06-21-56491d9f60f5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 210282 with status AP dated 2021-06-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda210282-2021-06-21-56491d9f60f5`](#source-fda-drugs-nda210282-2021-06-21-56491d9f60f5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda210282-2021-06-21-56491d9f60f5`](#source-fda-drugs-nda210282-2021-06-21-56491d9f60f5))

### Sources

<a id="source-fda-drugs-nda210282-2021-06-21-56491d9f60f5"></a>
- **Drugs@FDA application NDA210282 · original submission status AP · 2021-06-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA210282%22&limit=1) (`fda-drugs-nda210282-2021-06-21-56491d9f60f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA210282." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda210282-v1 SHA-256: d335f79fe269249a60750c0549a271830880db174b9db97004a8e2a6adbf0ff1.

---

<a id="fda-drugs-nda213645-v1"></a>

## Drugs@FDA application NDA213645

> The official Drugs@FDA dataset lists original submission 1 for NDA 213645 with status AP dated 2022-01-25, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213645:v1`
- Evidence domain: Regulatory
- Date in source: 2022-01-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213645/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda213645-v1
- Content SHA-256: `2510b2db63d7da12f5fa3c3f122dd82d7f539864496fe249f28302e6b9882506`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213645 ([`fda-drugs-nda213645-2022-01-25-f45af2a80e03`](#source-fda-drugs-nda213645-2022-01-25-f45af2a80e03))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213645 with status AP dated 2022-01-25, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda213645-2022-01-25-f45af2a80e03`](#source-fda-drugs-nda213645-2022-01-25-f45af2a80e03))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213645 with status AP dated 2022-01-25, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda213645-2022-01-25-f45af2a80e03`](#source-fda-drugs-nda213645-2022-01-25-f45af2a80e03))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213645-2022-01-25-f45af2a80e03`](#source-fda-drugs-nda213645-2022-01-25-f45af2a80e03))

### Sources

<a id="source-fda-drugs-nda213645-2022-01-25-f45af2a80e03"></a>
- **Drugs@FDA application NDA213645 · original submission status AP · 2022-01-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213645%22&limit=1) (`fda-drugs-nda213645-2022-01-25-f45af2a80e03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213645." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda213645-v1 SHA-256: 2510b2db63d7da12f5fa3c3f122dd82d7f539864496fe249f28302e6b9882506.

---

<a id="fda-drugs-nda217415-v1"></a>

## Drugs@FDA application NDA217415

> The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217415:v1`
- Evidence domain: Regulatory
- Date in source: 2023-01-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217415/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda217415-v1
- Content SHA-256: `076e4242870dd5035a5974d8b90b3051ff8ae1c6d5e02554bfccf2d4806ce5ec`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217415 ([`fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1`](#source-fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1`](#source-fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1`](#source-fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1`](#source-fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1))

### Sources

<a id="source-fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1"></a>
- **Drugs@FDA application NDA217415 · original submission status AP · 2023-01-30 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217415%22&limit=1) (`fda-drugs-nda217415-2023-01-30-e4af1a4b1aa1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217415." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda217415-v1 SHA-256: 076e4242870dd5035a5974d8b90b3051ff8ae1c6d5e02554bfccf2d4806ce5ec.

---

<a id="fda-drugs-nda217630-v1"></a>

## Drugs@FDA application NDA217630

> The official Drugs@FDA dataset lists original submission 1 for NDA 217630 with status AP dated 2024-11-21, and names daptomycin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217630:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217630/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda217630-v1
- Content SHA-256: `a250cfcdfba2370be1afa7196ee4dd885ee2cd641a0242dc63464afd57bf6e7c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217630 ([`fda-drugs-nda217630-2024-11-21-a14b2f8bb88c`](#source-fda-drugs-nda217630-2024-11-21-a14b2f8bb88c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217630 with status AP dated 2024-11-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda217630-2024-11-21-a14b2f8bb88c`](#source-fda-drugs-nda217630-2024-11-21-a14b2f8bb88c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217630 with status AP dated 2024-11-21, and names daptomycin among the application record's active ingredients. ([`fda-drugs-nda217630-2024-11-21-a14b2f8bb88c`](#source-fda-drugs-nda217630-2024-11-21-a14b2f8bb88c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217630-2024-11-21-a14b2f8bb88c`](#source-fda-drugs-nda217630-2024-11-21-a14b2f8bb88c))

### Sources

<a id="source-fda-drugs-nda217630-2024-11-21-a14b2f8bb88c"></a>
- **Drugs@FDA application NDA217630 · original submission status AP · 2024-11-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217630%22&limit=1) (`fda-drugs-nda217630-2024-11-21-a14b2f8bb88c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217630." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#fda-drugs-nda217630-v1 SHA-256: a250cfcdfba2370be1afa7196ee4dd885ee2cd641a0242dc63464afd57bf6e7c.

---

<a id="federal-register-2019-03129-v1"></a>

## Federal Register notice 2019-03129

> The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2019-03129:v1`
- Evidence domain: Regulatory
- Date in source: 2019-02-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-03129/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2019-03129-v1
- Content SHA-256: `f70f1ff37206176e27aaf7c299f8c8b3bbfc4fbc9bcc005e3353f9e3a7bc365b`

### Claims and source pins

#### Headline

Federal Register notice 2019-03129 ([`federal-register-2019-03129-3ecfbdcfd361`](#source-federal-register-2019-03129-3ecfbdcfd361))

#### Summary

The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2019-03129-3ecfbdcfd361`](#source-federal-register-2019-03129-3ecfbdcfd361))

#### Paragraph 1

The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2019-03129-3ecfbdcfd361`](#source-federal-register-2019-03129-3ecfbdcfd361))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-03129-3ecfbdcfd361`](#source-federal-register-2019-03129-3ecfbdcfd361))

### Sources

<a id="source-federal-register-2019-03129-3ecfbdcfd361"></a>
- **Federal Register notice 2019-03129 · published 2019-02-25 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-02-25/pdf/2019-03129.pdf) (`federal-register-2019-03129-3ecfbdcfd361`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-03129." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2019-03129-v1 SHA-256: f70f1ff37206176e27aaf7c299f8c8b3bbfc4fbc9bcc005e3353f9e3a7bc365b.

---

<a id="federal-register-2019-06385-v1"></a>

## Federal Register notice 2019-06385

> The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2019-06385:v1`
- Evidence domain: Regulatory
- Date in source: 2019-04-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-06385/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2019-06385-v1
- Content SHA-256: `35324797fd3729c12b260c0db4cb7d8f82b7c217966f60231a896c4938fa4a8b`

### Claims and source pins

#### Headline

Federal Register notice 2019-06385 ([`federal-register-2019-06385-18340d62e43b`](#source-federal-register-2019-06385-18340d62e43b))

#### Summary

The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2019-06385-18340d62e43b`](#source-federal-register-2019-06385-18340d62e43b))

#### Paragraph 1

The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2019-06385-18340d62e43b`](#source-federal-register-2019-06385-18340d62e43b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-06385-18340d62e43b`](#source-federal-register-2019-06385-18340d62e43b))

### Sources

<a id="source-federal-register-2019-06385-18340d62e43b"></a>
- **Federal Register notice 2019-06385 · published 2019-04-02 · Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-04-02/pdf/2019-06385.pdf) (`federal-register-2019-06385-18340d62e43b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-06385." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2019-06385-v1 SHA-256: 35324797fd3729c12b260c0db4cb7d8f82b7c217966f60231a896c4938fa4a8b.

---

<a id="federal-register-2020-23439-v1"></a>

## Federal Register notice 2020-23439

> The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2020-23439:v1`
- Evidence domain: Regulatory
- Date in source: 2020-10-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2020-23439/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2020-23439-v1
- Content SHA-256: `44c13cefb2112c3885490fca05d96673c8a099d21bcd78d300423562c48573f1`

### Claims and source pins

#### Headline

Federal Register notice 2020-23439 ([`federal-register-2020-23439-a738da553089`](#source-federal-register-2020-23439-a738da553089))

#### Summary

The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2020-23439-a738da553089`](#source-federal-register-2020-23439-a738da553089))

#### Paragraph 1

The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2020-23439-a738da553089`](#source-federal-register-2020-23439-a738da553089))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2020-23439-a738da553089`](#source-federal-register-2020-23439-a738da553089))

### Sources

<a id="source-federal-register-2020-23439-a738da553089"></a>
- **Federal Register notice 2020-23439 · published 2020-10-22 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2020-10-22/pdf/2020-23439.pdf) (`federal-register-2020-23439-a738da553089`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2020-23439." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2020-23439-v1 SHA-256: 44c13cefb2112c3885490fca05d96673c8a099d21bcd78d300423562c48573f1.

---

<a id="federal-register-2021-25111-v1"></a>

## Federal Register notice 2021-25111

> The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide.

- Evidence object: `story:federal-register-2021-25111:v1`
- Evidence domain: Regulatory
- Date in source: 2021-11-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-25111/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2021-25111-v1
- Content SHA-256: `d3a447ee9aeb4a6e39eb66da7ae794fcd539a1ae1956220884611acac1d8078a`

### Claims and source pins

#### Headline

Federal Register notice 2021-25111 ([`federal-register-2021-25111-f86de8c5a4dd`](#source-federal-register-2021-25111-f86de8c5a4dd))

#### Summary

The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide. ([`federal-register-2021-25111-f86de8c5a4dd`](#source-federal-register-2021-25111-f86de8c5a4dd))

#### Paragraph 1

The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide. ([`federal-register-2021-25111-f86de8c5a4dd`](#source-federal-register-2021-25111-f86de8c5a4dd))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-25111-f86de8c5a4dd`](#source-federal-register-2021-25111-f86de8c5a4dd))

### Sources

<a id="source-federal-register-2021-25111-f86de8c5a4dd"></a>
- **Federal Register notice 2021-25111 · published 2021-11-18 · Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-11-18/pdf/2021-25111.pdf) (`federal-register-2021-25111-f86de8c5a4dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-25111." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2021-25111-v1 SHA-256: d3a447ee9aeb4a6e39eb66da7ae794fcd539a1ae1956220884611acac1d8078a.

---

<a id="federal-register-2022-01693-v1"></a>

## Federal Register notice 2022-01693

> The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2022-01693:v1`
- Evidence domain: Regulatory
- Date in source: 2022-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-01693/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2022-01693-v1
- Content SHA-256: `a6b9773a76f5b2723c561d35b2e682d663fe04340e0393512ad51fb245e5141e`

### Claims and source pins

#### Headline

Federal Register notice 2022-01693 ([`federal-register-2022-01693-207eef43fa76`](#source-federal-register-2022-01693-207eef43fa76))

#### Summary

The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2022-01693-207eef43fa76`](#source-federal-register-2022-01693-207eef43fa76))

#### Paragraph 1

The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2022-01693-207eef43fa76`](#source-federal-register-2022-01693-207eef43fa76))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-01693-207eef43fa76`](#source-federal-register-2022-01693-207eef43fa76))

### Sources

<a id="source-federal-register-2022-01693-207eef43fa76"></a>
- **Federal Register notice 2022-01693 · published 2022-01-28 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-01-28/pdf/2022-01693.pdf) (`federal-register-2022-01693-207eef43fa76`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-01693." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2022-01693-v1 SHA-256: a6b9773a76f5b2723c561d35b2e682d663fe04340e0393512ad51fb245e5141e.

---

<a id="federal-register-2023-16775-v1"></a>

## Federal Register notice 2023-16775

> The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2023-16775:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-16775/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2023-16775-v1
- Content SHA-256: `6fbbe5459630c67901f6ec726235ccbc3250907a0b694fdc53c23188cc783e8e`

### Claims and source pins

#### Headline

Federal Register notice 2023-16775 ([`federal-register-2023-16775-bde2245cebc6`](#source-federal-register-2023-16775-bde2245cebc6))

#### Summary

The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2023-16775-bde2245cebc6`](#source-federal-register-2023-16775-bde2245cebc6))

#### Paragraph 1

The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2023-16775-bde2245cebc6`](#source-federal-register-2023-16775-bde2245cebc6))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-16775-bde2245cebc6`](#source-federal-register-2023-16775-bde2245cebc6))

### Sources

<a id="source-federal-register-2023-16775-bde2245cebc6"></a>
- **Federal Register notice 2023-16775 · published 2023-08-07 · Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-08-07/pdf/2023-16775.pdf) (`federal-register-2023-16775-bde2245cebc6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-16775." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2023-16775-v1 SHA-256: 6fbbe5459630c67901f6ec726235ccbc3250907a0b694fdc53c23188cc783e8e.

---

<a id="federal-register-2023-24120-v1"></a>

## Federal Register notice 2023-24120

> The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2023-24120:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-24120/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2023-24120-v1
- Content SHA-256: `4f4021168b5e0586034e09ba4df0ea57443b0084cfd2a04109666cc216110e09`

### Claims and source pins

#### Headline

Federal Register notice 2023-24120 ([`federal-register-2023-24120-51fba725a4d4`](#source-federal-register-2023-24120-51fba725a4d4))

#### Summary

The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2023-24120-51fba725a4d4`](#source-federal-register-2023-24120-51fba725a4d4))

#### Paragraph 1

The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2023-24120-51fba725a4d4`](#source-federal-register-2023-24120-51fba725a4d4))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-24120-51fba725a4d4`](#source-federal-register-2023-24120-51fba725a4d4))

### Sources

<a id="source-federal-register-2023-24120-51fba725a4d4"></a>
- **Federal Register notice 2023-24120 · published 2023-11-01 · Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-11-01/pdf/2023-24120.pdf) (`federal-register-2023-24120-51fba725a4d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-24120." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2023-24120-v1 SHA-256: 4f4021168b5e0586034e09ba4df0ea57443b0084cfd2a04109666cc216110e09.

---

<a id="federal-register-2025-06048-v1"></a>

## Federal Register notice 2025-06048

> The Federal Register published notice 2025-06048, attributed to FDA and its parent HHS department, on 2025-04-09. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-2025-06048:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-06048/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2025-06048-v1
- Content SHA-256: `7ae834e6fb0287c21d082c2f23bd80684f048dbae8e12b6f2f302959a592f5fe`

### Claims and source pins

#### Headline

Federal Register notice 2025-06048 ([`federal-register-2025-06048-c5417acda63b`](#source-federal-register-2025-06048-c5417acda63b))

#### Summary

The Federal Register published notice 2025-06048, attributed to FDA and its parent HHS department, on 2025-04-09. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2025-06048-c5417acda63b`](#source-federal-register-2025-06048-c5417acda63b))

#### Paragraph 1

The Federal Register published notice 2025-06048, attributed to FDA and its parent HHS department, on 2025-04-09. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-2025-06048-c5417acda63b`](#source-federal-register-2025-06048-c5417acda63b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-06048-c5417acda63b`](#source-federal-register-2025-06048-c5417acda63b))

### Sources

<a id="source-federal-register-2025-06048-c5417acda63b"></a>
- **Federal Register notice 2025-06048 · published 2025-04-09 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-04-09/pdf/2025-06048.pdf) (`federal-register-2025-06048-c5417acda63b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-06048." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-2025-06048-v1 SHA-256: 7ae834e6fb0287c21d082c2f23bd80684f048dbae8e12b6f2f302959a592f5fe.

---

<a id="federal-register-e6-1069-v1"></a>

## Federal Register notice E6-1069

> The Federal Register published notice E6-1069, attributed to FDA and its parent HHS department, on 2006-01-30. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-e6-1069:v1`
- Evidence domain: Regulatory
- Date in source: 2006-01-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-1069/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-e6-1069-v1
- Content SHA-256: `427617812607465940860bc3dc401c1a3ce9b94d2363312addbef7d98e9ae019`

### Claims and source pins

#### Headline

Federal Register notice E6-1069 ([`federal-register-e6-1069-6c4d46976def`](#source-federal-register-e6-1069-6c4d46976def))

#### Summary

The Federal Register published notice E6-1069, attributed to FDA and its parent HHS department, on 2006-01-30. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-e6-1069-6c4d46976def`](#source-federal-register-e6-1069-6c4d46976def))

#### Paragraph 1

The Federal Register published notice E6-1069, attributed to FDA and its parent HHS department, on 2006-01-30. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-e6-1069-6c4d46976def`](#source-federal-register-e6-1069-6c4d46976def))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-1069-6c4d46976def`](#source-federal-register-e6-1069-6c4d46976def))

### Sources

<a id="source-federal-register-e6-1069-6c4d46976def"></a>
- **Federal Register notice E6-1069 · published 2006-01-30 · Anti-Infective Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-01-30/pdf/E6-1069.pdf) (`federal-register-e6-1069-6c4d46976def`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-1069." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-e6-1069-v1 SHA-256: 427617812607465940860bc3dc401c1a3ce9b94d2363312addbef7d98e9ae019.

---

<a id="federal-register-e6-9225-v1"></a>

## Federal Register notice E6-9225

> The Federal Register published notice E6-9225, attributed to FDA and its parent HHS department, on 2006-06-14. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

- Evidence object: `story:federal-register-e6-9225:v1`
- Evidence domain: Regulatory
- Date in source: 2006-06-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-9225/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-e6-9225-v1
- Content SHA-256: `e29a3fa7a2eed0a51461d15dbf8575be2c48ba8c518c2cfd3a030be356977c85`

### Claims and source pins

#### Headline

Federal Register notice E6-9225 ([`federal-register-e6-9225-aa9efa18c401`](#source-federal-register-e6-9225-aa9efa18c401))

#### Summary

The Federal Register published notice E6-9225, attributed to FDA and its parent HHS department, on 2006-06-14. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-e6-9225-aa9efa18c401`](#source-federal-register-e6-9225-aa9efa18c401))

#### Paragraph 1

The Federal Register published notice E6-9225, attributed to FDA and its parent HHS department, on 2006-06-14. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin. ([`federal-register-e6-9225-aa9efa18c401`](#source-federal-register-e6-9225-aa9efa18c401))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-9225-aa9efa18c401`](#source-federal-register-e6-9225-aa9efa18c401))

### Sources

<a id="source-federal-register-e6-9225-aa9efa18c401"></a>
- **Federal Register notice E6-9225 · published 2006-06-14 · Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-06-14/pdf/E6-9225.pdf) (`federal-register-e6-9225-aa9efa18c401`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-9225." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#federal-register-e6-9225-v1 SHA-256: e29a3fa7a2eed0a51461d15dbf8575be2c48ba8c518c2cfd3a030be356977c85.

---

<a id="pubmed-pmid-31096056-daptomycin-v1"></a>

## Bone penetration of daptomycin in diabetic patients with bacterial foot infections.

> PubMed lists PMID 31096056 in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases as Clinical Trial, Journal Article, with publication-date metadata of 2019-05-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31096056-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-10-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31096056-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31096056-daptomycin-v1
- Content SHA-256: `35d9022f83c0e48afff7aa368175c277589af5b0d4734f9ba5be92cef2e50ca0`

### Claims and source pins

#### Headline

Bone penetration of daptomycin in diabetic patients with bacterial foot infections. ([`pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51`](#source-pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51))

#### Summary

PubMed lists PMID 31096056 in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases as Clinical Trial, Journal Article, with publication-date metadata of 2019-05-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51`](#source-pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51))

#### Paragraph 1

PubMed lists PMID 31096056 in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases as Clinical Trial, Journal Article, with publication-date metadata of 2019-05-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51`](#source-pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51`](#source-pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51))

### Sources

<a id="source-pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51"></a>
- **Bone penetration of daptomycin in diabetic patients with bacterial foot infections. · retained source version 1:2019-10-24:current:f6341e470f5172579d6a4704a9ad741586392cb4ed3dd95dee734e566b795c7e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31096056/) (`pubmed-observation-pmid-31096056-2019-10-24-f6341e470f51`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bone penetration of daptomycin in diabetic patients with bacterial foot infections." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31096056-daptomycin-v1 SHA-256: 35d9022f83c0e48afff7aa368175c277589af5b0d4734f9ba5be92cef2e50ca0.

---

<a id="pubmed-pmid-31182276-daptomycin-v1"></a>

## MprF-mediated daptomycin resistance.

> PubMed lists PMID 31182276 in International journal of medical microbiology : IJMM as Journal Article, Review, with publication-date metadata of 2019-06-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31182276-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31182276-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31182276-daptomycin-v1
- Content SHA-256: `30ee2889402e43127d670ebbd89d005f436b378882e9268c1523e0cc58587f1a`

### Claims and source pins

#### Headline

MprF-mediated daptomycin resistance. ([`pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee`](#source-pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee))

#### Summary

PubMed lists PMID 31182276 in International journal of medical microbiology : IJMM as Journal Article, Review, with publication-date metadata of 2019-06-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee`](#source-pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee))

#### Paragraph 1

PubMed lists PMID 31182276 in International journal of medical microbiology : IJMM as Journal Article, Review, with publication-date metadata of 2019-06-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee`](#source-pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee`](#source-pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee))

### Sources

<a id="source-pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee"></a>
- **MprF-mediated daptomycin resistance. · retained source version 1:2019-11-21:current:2cc8895a55ee3935e0925d49cd63d12fa33debafb22c2dd1071df55edbde7112** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31182276/) (`pubmed-observation-pmid-31182276-2019-11-21-2cc8895a55ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "MprF-mediated daptomycin resistance." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31182276-daptomycin-v1 SHA-256: 30ee2889402e43127d670ebbd89d005f436b378882e9268c1523e0cc58587f1a.

---

<a id="pubmed-pmid-31207214-daptomycin-v1"></a>

## Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.

> PubMed lists PMID 31207214 in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases as Journal Article, Systematic Review, with publication-date metadata of 2019-06-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31207214-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-09-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31207214-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31207214-daptomycin-v1
- Content SHA-256: `90455e7cf9287ef3b5060b5784f8321d2018e44c01910f1130f3f21f79732183`

### Claims and source pins

#### Headline

Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review. ([`pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3`](#source-pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3))

#### Summary

PubMed lists PMID 31207214 in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases as Journal Article, Systematic Review, with publication-date metadata of 2019-06-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3`](#source-pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3))

#### Paragraph 1

PubMed lists PMID 31207214 in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases as Journal Article, Systematic Review, with publication-date metadata of 2019-06-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3`](#source-pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3`](#source-pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3))

### Sources

<a id="source-pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3"></a>
- **Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review. · retained source version 1:2022-09-02:current:4535fcd472b33b7f2f040d3bb6f0ab7e0810894ab45c500d116e021e9b9bab1c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31207214/) (`pubmed-observation-pmid-31207214-2022-09-02-4535fcd472b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31207214-daptomycin-v1 SHA-256: 90455e7cf9287ef3b5060b5784f8321d2018e44c01910f1130f3f21f79732183.

---

<a id="pubmed-pmid-31284042-daptomycin-v1"></a>

## Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.

> PubMed lists PMID 31284042 in International journal of antimicrobial agents as Journal Article, Meta-Analysis, with publication-date metadata of 2019-07-05 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31284042-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31284042-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31284042-daptomycin-v1
- Content SHA-256: `b1ee50c502848d68203dfef726901915fcd23e7f76e46bf48f20837bcd1be5a2`

### Claims and source pins

#### Headline

Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. ([`pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e`](#source-pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e))

#### Summary

PubMed lists PMID 31284042 in International journal of antimicrobial agents as Journal Article, Meta-Analysis, with publication-date metadata of 2019-07-05 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e`](#source-pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e))

#### Paragraph 1

PubMed lists PMID 31284042 in International journal of antimicrobial agents as Journal Article, Meta-Analysis, with publication-date metadata of 2019-07-05 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e`](#source-pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e`](#source-pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e))

### Sources

<a id="source-pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e"></a>
- **Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. · retained source version 1:2020-05-14:current:ed409cd8283e20ea285c63918d098fd65431ea25e2839f56a6dd50c552b92e1b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31284042/) (`pubmed-observation-pmid-31284042-2020-05-14-ed409cd8283e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-31284042-daptomycin-v1 SHA-256: b1ee50c502848d68203dfef726901915fcd23e7f76e46bf48f20837bcd1be5a2.

---

<a id="pubmed-pmid-32321574-daptomycin-v1"></a>

## The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-a…

> PubMed lists PMID 32321574 in Antimicrobial resistance and infection control as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-04-22 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32321574-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32321574-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32321574-daptomycin-v1
- Content SHA-256: `3f8a846fc16bbb6ac8d6bd2df55fd75976ab3da4292c2a3bc6526070aaa6af4e`

### Claims and source pins

#### Headline

The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-a… ([`pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5`](#source-pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5))

#### Summary

PubMed lists PMID 32321574 in Antimicrobial resistance and infection control as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-04-22 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5`](#source-pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5))

#### Paragraph 1

PubMed lists PMID 32321574 in Antimicrobial resistance and infection control as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-04-22 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5`](#source-pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5`](#source-pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5))

### Sources

<a id="source-pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5"></a>
- **The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. · retained source version 1:2025-05-22:current:19e50c0b3ce5209eda853c39df424dda4aef27256d977c6567be01a45fa82a15** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32321574/) (`pubmed-observation-pmid-32321574-2025-05-22-19e50c0b3ce5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-a…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32321574-daptomycin-v1 SHA-256: 3f8a846fc16bbb6ac8d6bd2df55fd75976ab3da4292c2a3bc6526070aaa6af4e.

---

<a id="pubmed-pmid-32506921-daptomycin-v1"></a>

## Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin.

> PubMed lists PMID 32506921 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-06-08 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32506921-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-12-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32506921-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32506921-daptomycin-v1
- Content SHA-256: `6eb6a5f705e92f917b190d95b4b4b26856bcd15cd33dbfaec6951097b3325ffd`

### Claims and source pins

#### Headline

Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin. ([`pubmed-observation-pmid-32506921-2020-12-25-861a010df164`](#source-pubmed-observation-pmid-32506921-2020-12-25-861a010df164))

#### Summary

PubMed lists PMID 32506921 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-06-08 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32506921-2020-12-25-861a010df164`](#source-pubmed-observation-pmid-32506921-2020-12-25-861a010df164))

#### Paragraph 1

PubMed lists PMID 32506921 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-06-08 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32506921-2020-12-25-861a010df164`](#source-pubmed-observation-pmid-32506921-2020-12-25-861a010df164))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32506921-2020-12-25-861a010df164`](#source-pubmed-observation-pmid-32506921-2020-12-25-861a010df164))

### Sources

<a id="source-pubmed-observation-pmid-32506921-2020-12-25-861a010df164"></a>
- **Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin. · retained source version 1:2020-12-25:current:861a010df1642c5e31b5818abd1062fa7f6369625f33a5b5582751ca8db34891** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32506921/) (`pubmed-observation-pmid-32506921-2020-12-25-861a010df164`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32506921-daptomycin-v1 SHA-256: 6eb6a5f705e92f917b190d95b4b4b26856bcd15cd33dbfaec6951097b3325ffd.

---

<a id="pubmed-pmid-32526177-daptomycin-v1"></a>

## DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides.

> PubMed lists PMID 32526177 in Biochimica et biophysica acta. Biomembranes as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2020-06-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32526177-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-01-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32526177-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32526177-daptomycin-v1
- Content SHA-256: `5ac46c689bd328bd1b50779bef7c7404f5ba27b21eb807540d12b37494bd960d`

### Claims and source pins

#### Headline

DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides. ([`pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7`](#source-pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7))

#### Summary

PubMed lists PMID 32526177 in Biochimica et biophysica acta. Biomembranes as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2020-06-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7`](#source-pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7))

#### Paragraph 1

PubMed lists PMID 32526177 in Biochimica et biophysica acta. Biomembranes as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2020-06-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7`](#source-pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7`](#source-pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7))

### Sources

<a id="source-pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7"></a>
- **DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides. · retained source version 1:2021-01-06:current:33010fafa6c7a3d00988b0382303e9df43eb039718eb9c8380a466b7647e52a7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32526177/) (`pubmed-observation-pmid-32526177-2021-01-06-33010fafa6c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32526177-daptomycin-v1 SHA-256: 5ac46c689bd328bd1b50779bef7c7404f5ba27b21eb807540d12b37494bd960d.

---

<a id="pubmed-pmid-32533859-daptomycin-v1"></a>

## Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis.

> PubMed lists PMID 32533859 in Pharmacotherapy as Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, with publication-date metadata of 2020-07-06 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32533859-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32533859-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32533859-daptomycin-v1
- Content SHA-256: `0084a02ab44bd2c9ac429d72521bc42e9679d72d31d28c6a479907a14b22e615`

### Claims and source pins

#### Headline

Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. ([`pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b`](#source-pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b))

#### Summary

PubMed lists PMID 32533859 in Pharmacotherapy as Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, with publication-date metadata of 2020-07-06 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b`](#source-pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b))

#### Paragraph 1

PubMed lists PMID 32533859 in Pharmacotherapy as Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, with publication-date metadata of 2020-07-06 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b`](#source-pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b`](#source-pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b))

### Sources

<a id="source-pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b"></a>
- **Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. · retained source version 1:2021-05-18:current:9aeb2d6c9c4b60679345e07050095ebc990c401bdbbf08de21dad2796d4fafdf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32533859/) (`pubmed-observation-pmid-32533859-2021-05-18-9aeb2d6c9c4b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32533859-daptomycin-v1 SHA-256: 0084a02ab44bd2c9ac429d72521bc42e9679d72d31d28c6a479907a14b22e615.

---

<a id="pubmed-pmid-32725216-daptomycin-v1"></a>

## Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.

> PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32725216-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32725216-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32725216-daptomycin-v1
- Content SHA-256: `a48622325dbd9f4ce3c1c8fe678e16db03174e3640939056c99461909ae539d6`

### Claims and source pins

#### Headline

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. ([`pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3`](#source-pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3))

#### Summary

PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3`](#source-pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3))

#### Paragraph 1

PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3`](#source-pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3`](#source-pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3))

### Sources

<a id="source-pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3"></a>
- **Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. · retained source version 1:2026-11-09:current:205afecc44f3ea2cc9bafddb21e45abe5b54152c4e2e1fbefa78785f2962716c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32725216/) (`pubmed-observation-pmid-32725216-2026-11-09-205afecc44f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32725216-daptomycin-v1 SHA-256: a48622325dbd9f4ce3c1c8fe678e16db03174e3640939056c99461909ae539d6.

---

<a id="pubmed-pmid-32839217-daptomycin-v1"></a>

## Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis.

> PubMed lists PMID 32839217 in Antimicrobial agents and chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-10-20 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32839217-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32839217-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32839217-daptomycin-v1
- Content SHA-256: `81a7e01edd97e1977cb42be9ef65ba5d7a8168ea5b13d5ec06569801345f4f5b`

### Claims and source pins

#### Headline

Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis. ([`pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f`](#source-pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f))

#### Summary

PubMed lists PMID 32839217 in Antimicrobial agents and chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-10-20 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f`](#source-pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f))

#### Paragraph 1

PubMed lists PMID 32839217 in Antimicrobial agents and chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2020-10-20 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f`](#source-pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f`](#source-pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f))

### Sources

<a id="source-pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f"></a>
- **Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis. · retained source version 1:2021-06-17:current:e69dbd72447f88f48dfec108a5ae3112037e362712506d6832a4d660c9cfeb6b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32839217/) (`pubmed-observation-pmid-32839217-2021-06-17-e69dbd72447f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-32839217-daptomycin-v1 SHA-256: 81a7e01edd97e1977cb42be9ef65ba5d7a8168ea5b13d5ec06569801345f4f5b.

---

<a id="pubmed-pmid-33313994-daptomycin-v1"></a>

## Clinical Pharmacokinetics of Daptomycin.

> PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33313994-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33313994-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33313994-daptomycin-v1
- Content SHA-256: `61ce2c6be2eeaf2acf296fcd10bbafb3e8dfa86a88b3ed426ff65d8548238209`

### Claims and source pins

#### Headline

Clinical Pharmacokinetics of Daptomycin. ([`pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff`](#source-pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff))

#### Summary

PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff`](#source-pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff))

#### Paragraph 1

PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff`](#source-pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff`](#source-pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff))

### Sources

<a id="source-pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff"></a>
- **Clinical Pharmacokinetics of Daptomycin. · retained source version 1:2026-10-10:current:2b468a03ebff4db61a873fbcc4a0cec49d243a9d15c9ae4e4049d4af4fade6cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33313994/) (`pubmed-observation-pmid-33313994-2026-10-10-2b468a03ebff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical Pharmacokinetics of Daptomycin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33313994-daptomycin-v1 SHA-256: 61ce2c6be2eeaf2acf296fcd10bbafb3e8dfa86a88b3ed426ff65d8548238209.

---

<a id="pubmed-pmid-33563707-daptomycin-v1"></a>

## What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review.

> PubMed lists PMID 33563707 in Postgraduate medical journal as Journal Article, Review, with publication-date metadata of 2021-02-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33563707-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33563707-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33563707-daptomycin-v1
- Content SHA-256: `86a3d9b62d892a30ff87fe281a4083ff876a49b6fc77b6c501d42334d2cca628`

### Claims and source pins

#### Headline

What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review. ([`pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb`](#source-pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb))

#### Summary

PubMed lists PMID 33563707 in Postgraduate medical journal as Journal Article, Review, with publication-date metadata of 2021-02-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb`](#source-pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb))

#### Paragraph 1

PubMed lists PMID 33563707 in Postgraduate medical journal as Journal Article, Review, with publication-date metadata of 2021-02-09 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb`](#source-pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb`](#source-pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb))

### Sources

<a id="source-pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb"></a>
- **What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review. · retained source version 1:2021-12-23:current:2ec164e698bb8ef9857949549df7d2864e53627737776ad12c9fdae92c66f3e9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33563707/) (`pubmed-observation-pmid-33563707-2021-12-23-2ec164e698bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "What do beta-lactams add to vancomycin or daptomycin in the treatment of patients with methicillin-resistant Staphylococcus aureus bacteraemia? A review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33563707-daptomycin-v1 SHA-256: 86a3d9b62d892a30ff87fe281a4083ff876a49b6fc77b6c501d42334d2cca628.

---

<a id="pubmed-pmid-33620544-daptomycin-v1"></a>

## The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane.

> PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33620544-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33620544-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33620544-daptomycin-v1
- Content SHA-256: `42d15d198ba1d6ae0e7c6e186919a515c13da3d9892f5b65bc2eaef15744fb94`

### Claims and source pins

#### Headline

The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane. ([`pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44`](#source-pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44))

#### Summary

PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44`](#source-pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44))

#### Paragraph 1

PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44`](#source-pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44`](#source-pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44))

### Sources

<a id="source-pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44"></a>
- **The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane. · retained source version 1:2026-10-10:current:ee1e0bba6d44f7f7a6c3cb906aa41762ae209b51861bd7f409b68533ff31aaa1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33620544/) (`pubmed-observation-pmid-33620544-2026-10-10-ee1e0bba6d44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33620544-daptomycin-v1 SHA-256: 42d15d198ba1d6ae0e7c6e186919a515c13da3d9892f5b65bc2eaef15744fb94.

---

<a id="pubmed-pmid-33728980-daptomycin-v1"></a>

## Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 33728980 in Microbial drug resistance (Larchmont, N.Y.) as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-03-15 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33728980-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33728980-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33728980-daptomycin-v1
- Content SHA-256: `4d0e86af125866e8aecf3f252888a61e802afb8bca008202829c574d6e2a62b6`

### Claims and source pins

#### Headline

Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4`](#source-pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4))

#### Summary

PubMed lists PMID 33728980 in Microbial drug resistance (Larchmont, N.Y.) as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-03-15 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4`](#source-pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4))

#### Paragraph 1

PubMed lists PMID 33728980 in Microbial drug resistance (Larchmont, N.Y.) as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2021-03-15 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4`](#source-pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4`](#source-pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4))

### Sources

<a id="source-pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4"></a>
- **Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis. · retained source version 1:2021-12-21:current:a527b5764cf4c4d8c4b9beead91ab4e029e8a6cd73f6cbf021cc22b3ecba6571** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33728980/) (`pubmed-observation-pmid-33728980-2021-12-21-a527b5764cf4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-33728980-daptomycin-v1 SHA-256: 4d0e86af125866e8aecf3f252888a61e802afb8bca008202829c574d6e2a62b6.

---

<a id="pubmed-pmid-34439067-daptomycin-v1"></a>

## Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 34439067 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-08-21 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34439067-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34439067-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-34439067-daptomycin-v1
- Content SHA-256: `8aa36a5710183ca3ddf54cc8f081f00dc5448266f256dda868f4481f44fac202`

### Claims and source pins

#### Headline

Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc`](#source-pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc))

#### Summary

PubMed lists PMID 34439067 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-08-21 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc`](#source-pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc))

#### Paragraph 1

PubMed lists PMID 34439067 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-08-21 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc`](#source-pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc`](#source-pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc))

### Sources

<a id="source-pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc"></a>
- **Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis. · retained source version 1:2021-08-30:current:357f1c9be2cca17e982c1fb10ad3583e9bc0e3d9e7901e32cce90b1ec8d422a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34439067/) (`pubmed-observation-pmid-34439067-2021-08-30-357f1c9be2cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-34439067-daptomycin-v1 SHA-256: 8aa36a5710183ca3ddf54cc8f081f00dc5448266f256dda868f4481f44fac202.

---

<a id="pubmed-pmid-34568377-daptomycin-v1"></a>

## The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 34568377 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2021-09-10 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34568377-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34568377-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-34568377-daptomycin-v1
- Content SHA-256: `a72e3d278a656532df513978d3ea2df3c7cd4e65aa19791788f0f2537514a86e`

### Claims and source pins

#### Headline

The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403`](#source-pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403))

#### Summary

PubMed lists PMID 34568377 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2021-09-10 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403`](#source-pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403))

#### Paragraph 1

PubMed lists PMID 34568377 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2021-09-10 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403`](#source-pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403`](#source-pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403))

### Sources

<a id="source-pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403"></a>
- **The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis. · retained source version 1:2021-09-29:current:cb0299d3d403dd2956ec87ab3b2ee8abc579af689fa9f5bf75e6d262400c9994** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34568377/) (`pubmed-observation-pmid-34568377-2021-09-29-cb0299d3d403`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant Enterococcus faecalis and Enterococcus faecium Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-34568377-daptomycin-v1 SHA-256: a72e3d278a656532df513978d3ea2df3c7cd4e65aa19791788f0f2537514a86e.

---

<a id="pubmed-pmid-35656305-daptomycin-v1"></a>

## Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network…

> PubMed lists PMID 35656305 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35656305-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35656305-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-35656305-daptomycin-v1
- Content SHA-256: `48ab81323fcc9710c1737e06292656d615fc385699271dfe8940abbd885de56b`

### Claims and source pins

#### Headline

Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network… ([`pubmed-observation-pmid-35656305-2022-07-16-a856374139be`](#source-pubmed-observation-pmid-35656305-2022-07-16-a856374139be))

#### Summary

PubMed lists PMID 35656305 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35656305-2022-07-16-a856374139be`](#source-pubmed-observation-pmid-35656305-2022-07-16-a856374139be))

#### Paragraph 1

PubMed lists PMID 35656305 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35656305-2022-07-16-a856374139be`](#source-pubmed-observation-pmid-35656305-2022-07-16-a856374139be))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35656305-2022-07-16-a856374139be`](#source-pubmed-observation-pmid-35656305-2022-07-16-a856374139be))

### Sources

<a id="source-pubmed-observation-pmid-35656305-2022-07-16-a856374139be"></a>
- **Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network Meta-Analysis. · retained source version 1:2022-07-16:current:a856374139be33a35634469cdf1ea8c09ceaedcbbeb03edbf4e0194ecead86d5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35656305/) (`pubmed-observation-pmid-35656305-2022-07-16-a856374139be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant Staphylococcus aureus: A Network…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-35656305-daptomycin-v1 SHA-256: 48ab81323fcc9710c1737e06292656d615fc385699271dfe8940abbd885de56b.

---

<a id="pubmed-pmid-35786589-daptomycin-v1"></a>

## Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM.

> PubMed lists PMID 35786589 in Biological & pharmaceutical bulletin as Journal Article, Meta-Analysis, with publication-date metadata of 2022 (year precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35786589-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35786589-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-35786589-daptomycin-v1
- Content SHA-256: `9188b12247ec90cec5fdc0067b84eefb2cdafc123b8a68d453d314e11fa6f367`

### Claims and source pins

#### Headline

Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM. ([`pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520`](#source-pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520))

#### Summary

PubMed lists PMID 35786589 in Biological & pharmaceutical bulletin as Journal Article, Meta-Analysis, with publication-date metadata of 2022 (year precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520`](#source-pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520))

#### Paragraph 1

PubMed lists PMID 35786589 in Biological & pharmaceutical bulletin as Journal Article, Meta-Analysis, with publication-date metadata of 2022 (year precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520`](#source-pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520`](#source-pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520))

### Sources

<a id="source-pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520"></a>
- **Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM. · retained source version 1:2022-07-06:current:0aefe5ae5520aabdd588465d60683d8027834c7c5b46f139052d366468425d78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35786589/) (`pubmed-observation-pmid-35786589-2022-07-06-0aefe5ae5520`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-35786589-daptomycin-v1 SHA-256: 9188b12247ec90cec5fdc0067b84eefb2cdafc123b8a68d453d314e11fa6f367.

---

<a id="pubmed-pmid-36227704-daptomycin-v1"></a>

## Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.

> PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36227704-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-02-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36227704-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36227704-daptomycin-v1
- Content SHA-256: `9f612c47edddaacdece25af11f8f0080afe8f11cba7571e18d31f6e8b50cbe83`

### Claims and source pins

#### Headline

Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review. ([`pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5`](#source-pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5))

#### Summary

PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5`](#source-pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5))

#### Paragraph 1

PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5`](#source-pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5`](#source-pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5))

### Sources

<a id="source-pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5"></a>
- **Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review. · retained source version 1:2023-02-08:current:08bee0820bf5b17fc29b90c8a12407a6ca81cb639e3dd937043bca17fe49f27e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36227704/) (`pubmed-observation-pmid-36227704-2023-02-08-08bee0820bf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36227704-daptomycin-v1 SHA-256: 9f612c47edddaacdece25af11f8f0080afe8f11cba7571e18d31f6e8b50cbe83.

---

<a id="pubmed-pmid-36452455-daptomycin-v1"></a>

## Bacterial cell membranes and their role in daptomycin resistance: A review.

> PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36452455-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-02-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36452455-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36452455-daptomycin-v1
- Content SHA-256: `f9b990aa3497b65aab13fc2764da10e17b8dce981fe2ebcf53cada7b336362ad`

### Claims and source pins

#### Headline

Bacterial cell membranes and their role in daptomycin resistance: A review. ([`pubmed-observation-pmid-36452455-2023-02-17-fd9559885800`](#source-pubmed-observation-pmid-36452455-2023-02-17-fd9559885800))

#### Summary

PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36452455-2023-02-17-fd9559885800`](#source-pubmed-observation-pmid-36452455-2023-02-17-fd9559885800))

#### Paragraph 1

PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36452455-2023-02-17-fd9559885800`](#source-pubmed-observation-pmid-36452455-2023-02-17-fd9559885800))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36452455-2023-02-17-fd9559885800`](#source-pubmed-observation-pmid-36452455-2023-02-17-fd9559885800))

### Sources

<a id="source-pubmed-observation-pmid-36452455-2023-02-17-fd9559885800"></a>
- **Bacterial cell membranes and their role in daptomycin resistance: A review. · retained source version 1:2023-02-17:current:fd955988580048cd9ee8b38844fd2a5768df80c2561614a8de6a0f8dfe51c0b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36452455/) (`pubmed-observation-pmid-36452455-2023-02-17-fd9559885800`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bacterial cell membranes and their role in daptomycin resistance: A review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36452455-daptomycin-v1 SHA-256: f9b990aa3497b65aab13fc2764da10e17b8dce981fe2ebcf53cada7b336362ad.

---

<a id="pubmed-pmid-36870402-daptomycin-v1"></a>

## Daptomycin for the treatment of acute bacterial meningitis: A narrative review.

> PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36870402-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-05-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36870402-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36870402-daptomycin-v1
- Content SHA-256: `a0a4f16a2054f9d8c0e3d573b09216870903521f72883920feaeeb47bc1d867f`

### Claims and source pins

#### Headline

Daptomycin for the treatment of acute bacterial meningitis: A narrative review. ([`pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36`](#source-pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36))

#### Summary

PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36`](#source-pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36))

#### Paragraph 1

PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36`](#source-pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36`](#source-pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36))

### Sources

<a id="source-pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36"></a>
- **Daptomycin for the treatment of acute bacterial meningitis: A narrative review. · retained source version 1:2023-05-05:current:2d3922ef7b3692e2bcf7a1b9c00324fd3b6b04d603962ea1ca5d5e9b21faeec1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36870402/) (`pubmed-observation-pmid-36870402-2023-05-05-2d3922ef7b36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin for the treatment of acute bacterial meningitis: A narrative review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-36870402-daptomycin-v1 SHA-256: a0a4f16a2054f9d8c0e3d573b09216870903521f72883920feaeeb47bc1d867f.

---

<a id="pubmed-pmid-37622290-daptomycin-v1"></a>

## Daptomycin as an option for lock therapy: a systematic literature review.

> PubMed lists PMID 37622290 in Future microbiology as Journal Article, Systematic Review, with publication-date metadata of 2023-08-25 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37622290-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37622290-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-37622290-daptomycin-v1
- Content SHA-256: `f3f1369583d752c7d752593cadd8833898baa352849417b2218b95c0e4527a6d`

### Claims and source pins

#### Headline

Daptomycin as an option for lock therapy: a systematic literature review. ([`pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6`](#source-pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6))

#### Summary

PubMed lists PMID 37622290 in Future microbiology as Journal Article, Systematic Review, with publication-date metadata of 2023-08-25 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6`](#source-pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6))

#### Paragraph 1

PubMed lists PMID 37622290 in Future microbiology as Journal Article, Systematic Review, with publication-date metadata of 2023-08-25 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6`](#source-pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6`](#source-pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6))

### Sources

<a id="source-pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6"></a>
- **Daptomycin as an option for lock therapy: a systematic literature review. · retained source version 1:2024-03-22:current:b1d21e2c45b6428cd3d800609bbabb1fdb27e8c66fcbd3305dd30bbc9d56451f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37622290/) (`pubmed-observation-pmid-37622290-2024-03-22-b1d21e2c45b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin as an option for lock therapy: a systematic literature review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-37622290-daptomycin-v1 SHA-256: f3f1369583d752c7d752593cadd8833898baa352849417b2218b95c0e4527a6d.

---

<a id="pubmed-pmid-38606836-daptomycin-v1"></a>

## Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review.

> PubMed lists PMID 38606836 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, Case Reports, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38606836-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38606836-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-38606836-daptomycin-v1
- Content SHA-256: `d02210bdbc72520198f636af5cb8ff1cdd750bf90c7539138b4b4edbbc14cd2e`

### Claims and source pins

#### Headline

Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review. ([`pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f`](#source-pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f))

#### Summary

PubMed lists PMID 38606836 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, Case Reports, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f`](#source-pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f))

#### Paragraph 1

PubMed lists PMID 38606836 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, Case Reports, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f`](#source-pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f`](#source-pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f))

### Sources

<a id="source-pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f"></a>
- **Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review. · retained source version 1:2024-12-30:current:243fe11fcc8f0c15884849ea29665b8684442548071ed7bc8fc1f3115126c16a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38606836/) (`pubmed-observation-pmid-38606836-2024-12-30-243fe11fcc8f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-38606836-daptomycin-v1 SHA-256: d02210bdbc72520198f636af5cb8ff1cdd750bf90c7539138b4b4edbbc14cd2e.

---

<a id="pubmed-pmid-39028390-daptomycin-v1"></a>

## Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.

> PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39028390-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39028390-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39028390-daptomycin-v1
- Content SHA-256: `38daf5afa9e47341a585a6d61c9ae8fd989adaeda3f16fb38616c85d4ae3fc38`

### Claims and source pins

#### Headline

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series. ([`pubmed-observation-pmid-39028390-2025-07-11-b68891113230`](#source-pubmed-observation-pmid-39028390-2025-07-11-b68891113230))

#### Summary

PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39028390-2025-07-11-b68891113230`](#source-pubmed-observation-pmid-39028390-2025-07-11-b68891113230))

#### Paragraph 1

PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39028390-2025-07-11-b68891113230`](#source-pubmed-observation-pmid-39028390-2025-07-11-b68891113230))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39028390-2025-07-11-b68891113230`](#source-pubmed-observation-pmid-39028390-2025-07-11-b68891113230))

### Sources

<a id="source-pubmed-observation-pmid-39028390-2025-07-11-b68891113230"></a>
- **Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series. · retained source version 1:2025-07-11:current:b68891113230bbda81b3dd3371ed7ed87ecaaab9443f3cebef8a85b908161af2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39028390/) (`pubmed-observation-pmid-39028390-2025-07-11-b68891113230`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39028390-daptomycin-v1 SHA-256: 38daf5afa9e47341a585a6d61c9ae8fd989adaeda3f16fb38616c85d4ae3fc38.

---

<a id="pubmed-pmid-39216593-daptomycin-v1"></a>

## Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review.

> PubMed lists PMID 39216593 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Case Reports, Review, with publication-date metadata of 2024-08-30 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39216593-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39216593-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39216593-daptomycin-v1
- Content SHA-256: `8cda74d0875f886918db52f5b4fe245adbd6cb716e03629564e0bf39e336bbf1`

### Claims and source pins

#### Headline

Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review. ([`pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37`](#source-pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37))

#### Summary

PubMed lists PMID 39216593 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Case Reports, Review, with publication-date metadata of 2024-08-30 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37`](#source-pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37))

#### Paragraph 1

PubMed lists PMID 39216593 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Case Reports, Review, with publication-date metadata of 2024-08-30 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37`](#source-pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37`](#source-pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37))

### Sources

<a id="source-pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37"></a>
- **Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review. · retained source version 1:2025-05-19:current:6d095465cc37223f6b877d000808136b3f3b7c9e8a81b6b48516793efe9e89e5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39216593/) (`pubmed-observation-pmid-39216593-2025-05-19-6d095465cc37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39216593-daptomycin-v1 SHA-256: 8cda74d0875f886918db52f5b4fe245adbd6cb716e03629564e0bf39e336bbf1.

---

<a id="pubmed-pmid-39896981-daptomycin-v1"></a>

## Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections.

> PubMed lists PMID 39896981 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2025-01-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39896981-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-02-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39896981-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39896981-daptomycin-v1
- Content SHA-256: `6d2cccd407728e3eed241879460ab72af34babc6cb53ff29a12339133503fcfb`

### Claims and source pins

#### Headline

Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections. ([`pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e`](#source-pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e))

#### Summary

PubMed lists PMID 39896981 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2025-01-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e`](#source-pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e))

#### Paragraph 1

PubMed lists PMID 39896981 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2025-01-17 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e`](#source-pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e`](#source-pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e))

### Sources

<a id="source-pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e"></a>
- **Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections. · retained source version 1:2025-02-04:current:04fb875bb60e3e978a36d41908559433d9b89dc11e3261349f4722787d39e663** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39896981/) (`pubmed-observation-pmid-39896981-2025-02-04-04fb875bb60e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-39896981-daptomycin-v1 SHA-256: 6d2cccd407728e3eed241879460ab72af34babc6cb53ff29a12339133503fcfb.

---

<a id="pubmed-pmid-40558207-daptomycin-v1"></a>

## Use of Daptomycin to Manage Severe MRSA Infections in Humans.

> PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40558207-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40558207-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-40558207-daptomycin-v1
- Content SHA-256: `143bea4ee1209e51c0c22865b4c2fcdfeedb2b2e6cf73eff6bef5c84a970263a`

### Claims and source pins

#### Headline

Use of Daptomycin to Manage Severe MRSA Infections in Humans. ([`pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9`](#source-pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9))

#### Summary

PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9`](#source-pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9))

#### Paragraph 1

PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9`](#source-pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9`](#source-pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9))

### Sources

<a id="source-pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9"></a>
- **Use of Daptomycin to Manage Severe MRSA Infections in Humans. · retained source version 1:2025-06-27:current:c7c3acf182f9cf0e3ad1fe8e54aecebd6151afa8b88c9b3e6ecfd9d123885278** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40558207/) (`pubmed-observation-pmid-40558207-2025-06-27-c7c3acf182f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of Daptomycin to Manage Severe MRSA Infections in Humans." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-40558207-daptomycin-v1 SHA-256: 143bea4ee1209e51c0c22865b4c2fcdfeedb2b2e6cf73eff6bef5c84a970263a.

---

<a id="pubmed-pmid-41297715-daptomycin-v1"></a>

## Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin.

> PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41297715-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41297715-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-41297715-daptomycin-v1
- Content SHA-256: `01c650ecd26956465d0c01782bff5a91257e284616011ac9964bf9e78dca91e1`

### Claims and source pins

#### Headline

Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin. ([`pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07`](#source-pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07))

#### Summary

PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07`](#source-pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07))

#### Paragraph 1

PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07`](#source-pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07`](#source-pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07))

### Sources

<a id="source-pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07"></a>
- **Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin. · retained source version 1:2026-01-27:current:bafbfd031e07299d01d17c8ee8db25f2777e29c42645d1f31c15f9449763453a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41297715/) (`pubmed-observation-pmid-41297715-2026-01-27-bafbfd031e07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-41297715-daptomycin-v1 SHA-256: 01c650ecd26956465d0c01782bff5a91257e284616011ac9964bf9e78dca91e1.

---

<a id="pubmed-pmid-41321327-daptomycin-v1"></a>

## Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations.

> PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41321327-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41321327-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-41321327-daptomycin-v1
- Content SHA-256: `b37bf87e1a26c4a06af395e658a1857def8ef202c64618d42c92eec3f6ce6829`

### Claims and source pins

#### Headline

Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations. ([`pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c`](#source-pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c))

#### Summary

PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c`](#source-pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c))

#### Paragraph 1

PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c`](#source-pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c`](#source-pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c))

### Sources

<a id="source-pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c"></a>
- **Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations. · retained source version 1:2025-12-01:current:028ab37fdd7c0bfc66302cb792c3d8accf7787851c779c52cd477516da534772** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41321327/) (`pubmed-observation-pmid-41321327-2025-12-01-028ab37fdd7c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-41321327-daptomycin-v1 SHA-256: b37bf87e1a26c4a06af395e658a1857def8ef202c64618d42c92eec3f6ce6829.

---

<a id="pubmed-pmid-42869054-daptomycin-v1"></a>

## Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.

> PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42869054-daptomycin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42869054-daptomycin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-42869054-daptomycin-v1
- Content SHA-256: `04786909515f178a2b3efb37fbd918ecb33494833db65b9040d2478c85af363d`

### Claims and source pins

#### Headline

Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks. ([`pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e`](#source-pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e))

#### Summary

PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e`](#source-pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e))

#### Paragraph 1

PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e`](#source-pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e`](#source-pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e))

### Sources

<a id="source-pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e"></a>
- **Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks. · retained source version 1:2026-10-13:current:67e4429ba37e18c694ede362e8722bb5ea95b352086201573c9b1eac930fe47c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42869054/) (`pubmed-observation-pmid-42869054-2026-10-13-67e4429ba37e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/daptomycin.json#pubmed-pmid-42869054-daptomycin-v1 SHA-256: 04786909515f178a2b3efb37fbd918ecb33494833db65b9040d2478c85af363d.

